

INDEX

- Abatacept
 carcinogenicity studies, 421, 457
 immunomodulatory biopharmaceuticals, in vivo testing, 614–622
 reproductive/developmental toxicity testing, 363–371
 toxicity testing, 964
- Abciximab, toxicity testing, 955
- Abraxane™, toxicology studies of, 914
- Absorption, distribution, metabolism, and excretion (ADME) test systems
 Cerezyme® development, 527–528
 gene therapy safety evaluation, 740–742
 Japanese biopharmaceutical studies, 99
 preclinical safety evaluation, 56, 59
 protein scaffold therapeutics assessment, 637–646
- Acceptance criteria, recombinant proteins, 29–32
- Acid sphingomyelinase, development and regulation, 532–533
- Actimune®, toxicology studies, 932
- Activase®, toxicology studies, 932
- Acute toxicity studies
 design and cost estimates
 nonrodents, 853–854, 859, 862
 rodents, 853, 858–859
 oligonucleotides, 554–556
- Adalimumab
 binding properties, 282–283
 carcinogenicity studies, 427
 preclinical safety evaluation, 597
 reproductive/developmental toxicity testing, 363–370
 toxicity testing, 964
- Adeno-associated vectors (AAVs), gene therapy products, 717–718, 720–723
- Adenosine deaminase (ADA), 518
- Adenoviral vectors
 gene therapy products, 720–723
 viral vaccine evaluation, 697–698, 700
- Adipose tissue (AT), neo-organ development, cell sources, 810
- Adjuvant therapies, viral vaccine development, 692–695
- ADME test systems, preclinical safety evaluation, 62–64
- Adult stem cells, cell-based therapies, 759
- Affinity properties, monoclonal antibody tissue cross-reactivity assay, 193
- Agalsidase. *See* Fabrazyme®
- Alanine aminopeptidase, as predictive biomarker, 324
- Aldurazyme®
 animal models for, 655
 carcinogenicity studies, 445
 mucopolysaccharidoses I therapy, 518
 toxicology studies, 933
- Alefacept
 carcinogenicity studies, 457
 toxicology studies, 933
- Alemtusumab (Campath®), toxicity testing, 937
- Alferon, toxicology studies, 933
- Alglucosidase alpha. *See* Myozyme®
- Allogenic cell sources, neo-organ products, raw materials testing, 808, 811
- Anakinra
 carcinogenicity studies, 427, 455–456
 toxicity testing, 964
- Analogous products, preclinical safety evaluation, animal models, 56–57
- Animal models. *See also* Relevant species criteria; Species selection criteria
 acid sphingomyelinase development and regulation, 533
 blood product evaluation, 670–671
 coagulation factors, 675
 cell-based therapies, 759, 761
 toxicity studies, 770–771
 combination biologic/device products, 785, 803–804

- Animal models (*cont'd*)
- enzyme replacement therapies, Cerezyme®, 525–528
 - EU primate supply and use guidelines, 86
 - Fabrazyme® therapy, 528
 - gene therapy products
 - proof of concept studies, 729, 735
 - species selection criteria, 182
 - hypersensitivity reactions, preclinical evaluation, 493–494
 - ICH S6 protocols, Japanese species selection criteria, 95
 - immunoglobulin G clearance mechanisms
 - molecular determinants, 250
 - neonatal Fc receptor (FcRn), 257
 - immunomodulatory biopharmaceuticals, in vivo testing, 622
 - immunotoxin evaluation, 654–655
 - lysosomal disease therapies, 521
 - Myozyme® development and regulation, 531
 - neo-organ product testing, selection criteria, 815, 817, 819
 - oligonucleotides, subchronic/chronic toxicity studies, 556–565
 - immunologic effects, 561
 - renal function, 563, 565
 - pharmacodynamics
 - binding properties, 282–283
 - overview, 265
 - species specificity, 277–282
 - pharmacokinetics, 282–288
 - disposition, 284–286
 - immunogenicity, 286–287
 - preclinical safety evaluation, 52, 60
 - analogous products, 56–58
 - cross-reactivity studies, 208
 - disease models
 - abnormal kinetic behavior of compound, 303
 - hyperlipidemia, 298
 - immunogenicity, 303–304
 - indications for, 412, 461
 - overview, 296
 - translational research, humanized models, 296–297, 299
 - undesirable progression evaluation, 302
 - numbers and gender, study design and, 913, 915
 - pharmacology and toxicology, 300
 - species selection criteria, 182
 - protein scaffold therapeutics assessment, animal selection criteria, 633–641
 - reproductive/developmental toxicity testing, monoclonal antibodies, 360–370
 - safety pharmacology
 - biopharmaceuticals, 314–316
 - predictive failure, toxicology studies, 324–325
 - somatic stem cells, 759
 - tissue cross-reactivity assay, monoclonal antibodies, 216, 232, 234, 236
 - human tissue vs., 216–217
 - toxicity studies
 - human/primate molecular pharmacological activity, 348–349
 - nonrodent molecular pharmacological activity, 347
 - peptides, preclinical assessment, 501–502, 506
 - rodents/nonrodents, 344–345
 - transgenic/knock-out- models, 348–349
- Animal proteins, Japanese points-to-consider documents, 101
- Antibodies
- biopharmaceuticals and formation of, safety pharmacology testing, 315–316
 - classification and evolution, 210–211, 213
 - immunogenicity risk
 - administration route, 739, 973
 - biological activities, 480
 - concomitant therapy, 481
 - impurities, 481
 - length of treatment, 475, 480
 - patient characteristics, 475, 481
 - product modifications, 481
 - Japanese points-to-consider documents, 102–104
 - orientation, combination biologic/device products, 785, 803–804
 - pharmacokinetics assays, immunogenicity, 283–288
 - potential elution, combination biologic/device products, 783, 791
- Antibody-coated stent
- pharmacologic/toxicologic studies, 793–795
 - preclinical evaluation, 774, 807
- Antibody-dependent cell-mediated cytotoxicity (ADCC)
- antibody activation, 210–215
 - antibody classification and evolution, 208–214
 - ex vivo biologic effect, relevant species criteria, 188–189
 - monoclonal antibodies, 234, 236—237
- Antibody screening assays, preclinical safety evaluation, 59
- Antigen-presenting cells (APCs), cell-based therapies, 690
- Antihemophilic factor (AHF), evolution of, 670
- Anti-interferon antibodies, hypersensitivity, 487–491
- Antisense oligonucleotides (ASOs)
- animal disease models, 297, 301, 304
 - central nervous system safety, 551
 - hybridization-dependent toxicities, 545–546
 - immunotoxicity studies, 566–567
 - safety pharmacology studies, 551–554
 - single-stranded structures, 578
- Anti-tumor monoclonal antibodies
- hypersensitivity reactions, preclinical evaluation, 493–494
 - immune complex targeting, 237, 240
- Apligraf®
- development of, 804–806
 - toxicity studies, 934

- Apoptosis, safety pharmacology applications, 916, 945
- Approval process, biopharmaceuticals
in European Union, 14–15
in United States, 9
- Aptamers
basic properties, 473, 569
chemical properties, 643
clotting inhibition, 555–556
pharmacokinetics, 542, 544
- aPTT prolongation, phosphorothioate
oligonucleotide acute toxicity, 555–556
- AranespTM, toxicity studies, 935
- AspB10, carcinogenicity studies, 510, 514
- Assay strategies
comparability testing, 171–177
enzyme replacement therapy development, 526
immunogenicity risk, 482, 484–485
oligonucleotide therapeutics, genotoxicity studies, 545–549
tissue cross-reactivity assay, monoclonal antibodies, 214–219
- Assessment of developmental and reproductive toxicity (DART). *See* Reproductive/developmental toxicity studies
- Atypical tumor promoters (ATPs), immunomodulatory biopharmaceuticals, 607, 610
models of, 640
in vitro testing, 624, 655
in vivo testing, 524, 820
- Audit reports, good laboratory practice requirements, preclinical development programs, 811
- Autoimmunity
clinical assessment, 474, 513
future research issues, 494–495
preclinical biopharmaceutical evaluation, 491, 493, 495
regulatory guidance, 491
viral vaccine and induction of, 686, 688
- Avidin, biotin binding affinity
background staining, 226
monoclonal antibody tissue cross-reactivity assay, 193
- Avonex®, toxicity testing, 935
- Background staining, tissue cross-reactivity assay, 219–220
monoclonal antibodies, 226
- Bare metal stents (BMS), combination biologic/device products, 797
- Basic Local Alignment Search Tool (BLAST)
cell-based therapies, toxicity studies, 761
monoclonal antibodies, 209
preclinical safety evaluation, cross-reactivity studies, 52
- Basophilic granules, oligonucleotide subchronic/chronic toxicity, 558
- Becaplermin, carcinogenicity studies, 438, 460–461
- Betaseron®, toxicity testing, 936
- Bevacizumab, reproductive/developmental toxicity testing, 366, 368, 370, 372, 935
- Bexxar®, toxicity testing, 936
- Binding assays
ex vivo/in vitro biopharmaceutical interaction, relevant species selection criteria, 194–196
pharmacodynamics studies, species specificity, 282, 284
- Bioanalytical method validation, preclinical safety evaluations, cost estimates, 904
- Bioburden testing, preclinical safety assessments, quality controls, 917
- Bioconjugates, Japanese points-to-consider documents, 102
- Biodistribution assays
design and cost estimates, Sprague-Dawley rats, 855, 873–874, 876, 878
gene therapy safety evaluation, 739–742
immunoglobulin G, 239, 266
in interstitial fluid compartment, 241, 244, 247
intravascular into interstitial egress, 243–244, 247
tissue-specific transport/uptake barriers, 241, 246
viral vaccine development, 698, 702
- Bioequivalence, generic drugs and, 163–164
- Biogenerics, defined, 161, 164–165
- Biologics. *See also* Biopharmaceuticals
combination biologic/device products
antibody-coated stent example, 783
basic properties, 787, 789
biologic orientation assessment, 783, 790
functionality assessment, 786–787
pharmacological/toxicological assessment, 791–794, 796
regulatory issues, 783, 788
testing strategies, 789
conventional, 103
first-in-human (FIH) trials guidelines, starting dose calculations, 975
good laboratory practice requirements for, 839
non-protein-peptide-based, 103
peptide-based, 102
preclinical development programs
alternative plans for, 148
cell line, manufacturing process, formulation, or administrative route changes, 153
clinical development plan, 132
critical decision making, 146–147
design for, 128
essential components for, 135–136
general assumptions, 131
integrated plans, 144
limitations of, 148
phase 1 supports, 137–140
phase 2 supports, 140–142

- Biologics** (*cont'd*)
 phase 3 supports, 142–144
 planning guidelines, 156–157
 relevant species, absence of, 152
 specific assumptions, 134–135
 therapeutic target, mechanism of action, and
 clinical indication, 131
 traditional development plans, 135
 preclinical safety assessments, bioburden testing
 of, 913
 properties of, 128
 protein-based, 100–102
 recombinant protein activity, 30
 regulatory guidelines, 130
Biologics license supplement (BLS), comparability
 testing following marketing approval,
 174
Biomarkers
 cell-based therapies, 766
 protein scaffold therapeutics assessment,
 646–647
 safety pharmacology applications,
 biopharmaceutical toxicology protocols,
 324–325
Biomaterials, neo-organ products, scaffold
 materials, 814
Biopharmaceuticals
 basic properties, xii
 in European Union
 approval requirements, 15
 definitions, 11–12
 marketing and postapproval requirements, 15
 regulations, 12–13
 research and development requirements, 13
 first-in-human trials, safe starting doses
 calculation protocols, 978
 dose escalation/top dose limits, 982
 future research issues, 982–983
 overview, 845
 post-phase I calculations, 981
 preclinical-to-clinical dosing transition, 974–975
 protein therapeutics, estimation examples, 979
 protein therapeutics, human equivalent dose
 calculations, 978–979
 safety profiles, 972
 genotoxicity testing, 337–338
 good laboratory practice requirements and
 practices, basic principles, 832
 in Japan, 16–17
 preclinical toxicity testing, approved compound
 survey, 964
 QT liability evaluation, 318
 safety pharmacology for, 313–315
 predictive safety biomarkers, toxicology
 protocols, 324
 toxicity studies
 carcinogenicity testing, 965
 future research issues, 358
 genotoxicity, 909
 immunotoxicity testing, 350–352, 966
 relevant species criteria
 human/primate molecular pharmacological
 activity, 348
 nonrodent molecular pharmacological
 activity, 345
 rodents/nonrodents, 344
 repeat-dose toxicity testing, 964–965
 reproductive/developmental toxicity, 965
 single-dose toxicity testing, 963
 specific compound survey, 931
 tissue cross-reactivity testing, 963
 in United States
 approval requirements, 9
 definitions, 4–5
 marketing and postapproval requirements, 9
 regulations, 5–7
 research and development requirements, 13
Bioreactors
 biopharmaceutical production and, 22
 enzyme replacement therapy development, 525
Biosafety levels, good laboratory practice
 requirements and practices, 831
Biosensors, neo-organ products and integration of,
 824
Biotechnology products
 U.S. marketed products list, 114
 U.S. regulation of, 112–113
Biotin, monoclonal antibody tissue cross-reactivity
 assay, 220–222
 background staining, 226
Bivalrudin, chronic toxicity studies, 508
**Blood-brain barrier, immunoglobulin G transport/
 uptake, 246–247**
Blood products, preclinical safety evaluation
 coagulation disorders, gene therapy for, 677
 future research issues, 677–678
 genetically deficient protein diseases, 673
 hemoglobin-based oxygen carriers, 672
 immunogenicity, 675–676
 immunoglobulins, 561
 overview, 707
 recombinant coagulation factors, 676–677
 replacement therapy, coagulation factors, 675
 sampling and maximum blood volume criteria, 926
Blood urea nitrogen (BUN)
 oligonucleotide toxicity and, 564–565
 as predictive biomarker, safety pharmacology
 studies, 324
Body fluids, comparative volumes, preclinical
 safety evaluation, 920
Body surface area, first-in-human (FIH) trials,
 human equivalent dose calculations, 979
Bone implants, tissue-engineered product
 development for, 804
Bone morphogenetic protein (BMP), tissue-
 engineered product development with,
 804
Bovine gamma globulin, immune complex disease,
 236
Breast tissue, immunoglobulin G clearance, 257

- Candidate selection, monoclonal antibody tissue cross-reactivity assay, 220
- Carcinogenicity studies
 biopharmaceuticals, 965
 design and cost estimates
 CD@-1 mice, 895
 Sprague-Dawley rats, 869
 transgenic mice, 871
 immunomodulators
 clinical trials, 601
 future research issues, 624
 overview, 624
 potential tumor progression, 609–610
 promoter identification and characterization models, 621
 in vitro mechanisms, 611
 in vivo systems, 611
 risk assessment and classification, 621–624
 testing protocols, 602
 tumor promotion, 607–609
 immunotoxins, 661
- Japanese points-to-consider documents, 107
- oligonucleotide therapeutics, 568
- peptides, 509–512
- preclinical safety evaluation
 basic principles, 403
 carcinogenic potential assessment, 413–424, 426
 cell line selection, 410
 cellular-based therapies, 410
 clinical indications, 412
 gene therapies, 411
 human malignancy patterns, 404
 immunomodulators, 427–428
 indications for, 405
 peptide hormone and growth factors, 406, 457–458
 proliferation indexes, repeat-dose chronic toxicity studies, 423
 risk communication and management, 463
 rodent bioassay, 421
 limitations, 468–469
 short-term assay, 421–422
 transgenic animals, 424
 tumor host-resistance models, 423–424
 in vitro cell proliferation, 425
- toxicity studies, rodents/nonrodents
 pharmacological activity, 346
- U.S. points-to-consider documents, 120
- viral vaccine development, 698
- Cardiovascular safety evaluations
 biopharmaceuticals, QT liability evaluation, 318–320
 design and cost estimates
 cloned hErG expression, 890–891
 comparative characteristics, 921
 dog Purkinje fibers, action potential parameters, 892
 nonrodent hemodynamic function, 854
 nonrodent toxicity studies, pharmacological activity, 346
 oligonucleotide pharmacology, 552
 subchronic/chronic toxicity, 556
- Carticel®, toxicity testing, 937
- Case-by-case protocol (ICH S6)
 animal disease models, 297
 autoimmunity and hypersensitivity, 491
 blood product evaluation guidelines, 671
 carcinogenicity studies of biopharmaceuticals, 408, 510
 drug and biologics development program design, 130
 enzyme replacement therapies, 525, 534
 evolution of, 49
 genotoxicity testing, 506
 immunotoxin evaluation, 654
 implementation in EU, 68, 70
 Japanese implementation of
 in vivo studies, 96
 Japanese implementation of ICH S6
 ADME studies, 99
 animal species selection, 95
 antibodies, 102
 biopharmaceutical categories, 96
 carcinogenicity studies, 105–106
 conventional biologics, 103
 electrophysiology, in vitro studies, 108
 future points-to-consider documents, 107
 genotoxicity studies, 106–107
 high dose selection, 94
 JPMA questionnaire survey, 95–96
 metabolism studies, 104
 non-protein-peptide-based biologics, 103
 peptide-based biologics, 102
 points-to-consider document, 99–100, 103, 107
 protein-based biologics, 103
 repeat-dose toxicity studies, 104–105
 reproductive/developmental toxicity studies, 98
 single-dose toxicity studies, 104
 toxicological effects and pharmacological action, 103
 in vitro studies, 89
- monoclonal antibody guidelines, 208, 594, 597
- oncology drugs, preclinical safety evaluation, 583–584
- peptide toxicity assessment, 502–503
- pharmacokinetics/toxicokinetics studies, 925
- preclinical safety assessment design, 914
- protein scaffold therapeutics, 634–637
- quality controls, preclinical safety assessments, 917
- relevant species criteria, 181–182
- reproductive/developmental toxicity studies guidelines, 358
- species selection criteria, 914
- United States implementation of
 administration/dose selection, 116
 animal species selection, 115–116
 carcinogenicity studies, 120
 exposure limits, 118
 general principles, 115

- Case-by-case protocol (ICH S6) (*cont'd*)
 genotoxicity studies, 119
 historical perspective, 113–115
 immunogenicity, 117
 immunotoxicity, 119
 local tolerance, 120
 regulatory issues, 109–112
 repeat-dose studies, 118
 reproductive/developmental studies, 119
 safety pharmacology/single-dose studies, 118
- Categorical exclusion criteria, environmental assessment and, 33
- CD@-1 mice, carcinogenicity studies, design and cost estimates, 870
- cDNA, enzyme replacement therapy development, 524
- CEA-Scan®, toxicity testing, 937
- Cell-based therapies
 carcinogenicity studies, 408
 future research issues, 776
 preclinical safety evaluation
 adult stem cells, 759
 endothelial progenitor cells, 760
 exposure assessment, 767
 ex vivo activated mononuclear leukocytes, 758–759
 future research issues, 774–775
 genotoxicity, 771
 hematopoietic stem cells, 759
 historical background, 766
 human embryonic stem cells, 762
 living autologous cells, 759–760
 local tolerance, 773
 mesenchymal stem cells, 759–760
 pharmacology, 766
 pre-preind filing in U.S., 773
 regulatory guidelines, 755
 reproductive/developmental toxicity, 771
 safety issues, 784
 safety pharmacology, 768
 somatic cell products, 778
 stem cell based therapies, 762
 toxicity studies, 770
 transition to clinical trials, 774
 tumorigenicity, 771
 xenogenic cells, 761
 somatic cell products, pharmacology/toxicology, 787
- Cell labeling, cell-based therapies exposure assessment, 767
- Cell lines
 biologics, preclinical development programs, 156–158
 carcinogenicity studies, biopharmaceutical production, 421
 enzyme replacement therapy development, 525
 neo-organ development and, raw material testing, 808
- Cell-mediated immunity
 integrated preclinical-clinical immunotoxicity assessments, 325
 preclinical safety evaluation, 47–51
 viral vaccine development and, 701
- Cell proliferation
 carcinogenicity studies, in vitro testing, 426
 safety pharmacology applications, 325
- Cellular fate, somatic stem cells, 769
- Cellular systems, manufacturing criteria, 28
- Center for Biologics Evaluation and Research (CBER)
 cell-based therapies guidelines, 753
 combination biologic/device products, definitions, 785
 gene therapy product regulation, 720
 ICH S6 implementation, 112
 neo-organ development, 805
- Center for Devices and Radiological Health (CDRH)
 combination biologic/device products, 786
 neo-organ development, 805
- Center for Drug Evaluation and Research (CDER)
 combination biologic/device products, 785–792
 ICH S6 implementation, 112
 neo-organ development, 804
- Centralized procedure (CP), marketing authorization applications (EU), 75
- Central nervous system (CNS)
 nonrodent toxicity studies, pharmacological activity, 347
 oligonucleotide safety pharmacology, 551–552
 toxicology studies, biopharmaceuticals, predictive safety biomarkers, 323
- Cerezyme®
 animal models for, 521
 carcinogenicity studies, 442
 historical background, 521
 regulatory guidelines for, 526
 toxicity testing, 938
- Cetuximab
 reproductive/developmental toxicity testing, 372
 toxicity testing, 940
- Chemotherapeutic agents, reproductive/developmental toxicity testing, 371–374
- Chimeric monoclonal antibodies, 588
- Chimpanzees. *See also* Nonhuman primates (NHP)
 preclinical safety evaluation, monoclonal antibodies, 583
 reproductive/developmental toxicity testing, monoclonal antibodies, 380
 toxicity testing in, 353
- Cholesterol ester transfer protein (CETP), transgenic humanized mouse models, 299
- Chromosomal aberrations, in vitro testing, design and cost estimates, 855, 891–897
- Chronic toxicity studies
 design and cost estimates
 nonrodents, 854, 867

- rodents, 854, 867
- EU guidelines for, 84
- oligonucleotide therapeutics, 539–547
- peptides, 512–513
- Class labeling, protein scaffold therapeutics
 - assessment, 643
- Clearance mechanisms, immunoglobulin G, 266–270
 - breast, 257
 - colon, 259
 - cytosolic transport, epithelial/mesothelial tissue, 262
 - erythrocyte CR1 clearance, 262
 - FcRn transport, 254–255
 - kidney, 256
 - liver, 260
 - lungs, 226
 - lymphatic clearance, 248
 - mononuclear phagocyte system/endothelial cell clearance, 245–249
 - ovary, 257
 - placenta and uterus, 258
 - plasma clearance and tissue catabolism, 243
 - plgR on epithelial cells, 272
 - salivary glands, 274
 - seminal fluid, 258
 - skin, 261
 - thyroid, 261
 - tissue-specific transport, 253–261
- Clinical indications, drugs and biologics preclinical development programs, 132
- Clinical trials
 - biologic/drug preclinical development programs, added value of, 156
 - cell-based therapies guidelines, 759–761
 - comparability testing and, 174–175
 - drugs and biologics preclinical development program support for, 156
 - EU regulations for, 90–91
 - first-in-human (FIH) trials guidelines, preclinical transition to, 975
 - immunomodulatory biopharmaceuticals, 624–625
 - neo-organ prototypes, 812–816
 - nonhuman primate reproductive/developmental toxicity testing, endpoint criteria, 382
 - oncology drugs, preclinical safety evaluation, 580
 - pathology parameters, 901
- Coagulation disorders, blood products therapies, evaluation of, 678
- Coagulation factors, blood product evaluation guidelines, 680
- Colon, immunoglobulin G clearance mechanisms, 252
- Combination biologic/device products
 - neo-organ development, regulatory guidelines, 804–807
 - preclinical safety evaluation
 - antibody-coated stent example, 789
 - basic properties, 787
 - biologic orientation assessment, 790
 - functionality assessment, 787
 - pharmacological/toxicological assessment, 793–795
 - potential elution species, 791
 - regulatory issues, 788
 - testing strategies, 819
- Committee for Medicinal Products for Human Use (CHMP)
 - biogenerics regulations, 164
 - gene therapy product regulation, 718
- Comparability testing
 - defined, 162
 - EU guidelines for biopharmaceuticals, 88
 - general principles and practices, 167
 - clinical considerations, 172
 - immunogenicity, 173
 - indications for, 169
 - manufacturing changes, 170
 - physicochemical characterization, 171
 - preclinical considerations, 171
 - manufacturing alterations and, 37
 - new manufacturing technologies and, 39
 - non-regulatory applications, 174
 - post-marketing approval, regulatory submissions for, 175
 - product attributes, preclinical safety evaluation and, 51
 - regulatory guidance
 - EMA guidelines, 167
 - FDA guidelines, 167
 - ICH guidelines, 168
- Comparative physiological parameters, preclinical safety assessments, 920
- Complement activation, antibody effects, 215
- Complementarity determining region (CDR)
 - antibody effects on, 215
 - monoclonal antibodies, 209
 - biotin binding affinity, 222
 - immune complex disease, 237
 - nonspecific staining, tissue cross-reactivity studies, 256–257
 - specific staining, tissue cross-reactivity studies, 226
- Complement-dependent cytotoxicity (CDC)
 - ex vivo biologic effect, relevant species criteria, 189
 - protein binding and cleavage, 215
- Complement inhibition, phosphorothioate oligonucleotide acute toxicity, 555
- Concentration selection, monoclonal antibody tissue cross-reactivity assay, 223
- Concomitant therapy, immunogenicity risk, 481
- Confidentiality agreements, good laboratory practice requirements, 838
- Context protocols, cross-reactivity assays, 230
- Contractile filament tissue, cross-reactivity assay pattern classifications, 231
- Contract research organizations (CROs)
 - good laboratory practice requirements, 831

- Contract research organizations (CROs) (*cont'd*)
 preclinical safety evaluations
 cost estimates, 855
 selection criteria, 853
- Conventional tumor promoters (CTPs),
 immunomodulatory biopharmaceuticals,
 606–607
 in vitro testing, 611
 in vivo testing, 624
- Core battery approach, safety pharmacology, small
 molecules, 312
- Cost estimates, preclinical safety evaluation
 acute toxicology studies
 nonrodents, 854, 859
 rodents, 854, 858
 analytical/bioanalytical costs, 904
 biodistribution studies, 854, 877
 carcinogenicity studies
 CD@-1 mice, 851, 871
 Sprague-Dawley rats, 854, 869
 transgenic mice, 854, 871
 cardiovascular function
 dog Purkinje fiber action potentials, 892
 hemodynamics and, 886
 hERG gene expression, 891
 chronic toxicology studies
 nonrodents, 854, 866, 869
 rodents, 831, 851, 853–856
 clinical pathology parameters, 901, 926
 dose escalation studies
 nonrodents, 851, 853–854
 rodents, 851, 853–856
 Draize scores, 903
 embryofetal development and toxicokinetics
 rabbits, 851, 854
 rats, 851–856
 GLP compliance costs, 843, 846
 ICH guidance documents, 905, 911
 immunogenicity studies, Sprague-Dawley rats,
 946
 immunotoxicity studies, 854, 906
 live assays, 873–874
 lymphoma mutagenesis, 896, 909
 micronucleated polychromatic erythrocytes, 852,
 895
 neuropharmacology studies, 852, 887
 organ weights, 873
 overview, 831, 838
 phototoxicity studies, 851, 876
 pre- and postnatal development, 852, 884
 pulmonary assessment, 852, 889
 reproductive/developmental toxicity studies, 358,
 371, 381
 safety pharmacology, rodent/nonrodent studies,
 766, 854, 886
 special stains, 852, 904
 subchronic toxicology studies
 nonrodents, 851, 853–854
 rodents, 831, 851, 853–856
 tissue cross-reactivity, 236, 238, 240
 tissue preservation, 875, 877
 vaccine studies, 831, 844
 in vitro chromosomal aberration, 852, 897
- Council of Ministers (EU), structure and function,
 70
- CpG oligonucleotides
 hybridization-independent toxicities, 545
 toxicity studies, lymphohistiocytic infiltrates,
 529, 548
- C-reactive protein (CRP), as biomarker, safety
 pharmacology applications, 321, 323
- Critical decision-making, drugs and biologic
 preclinical development programs,
 146–148
- Critical path development, gene therapy, 714
- Cross-contamination issues, neo-organ
 development, 808
- Cross-reactivity studies
 basic principles, 103
 biologics, preclinical development programs, 121
 monoclonal antibodies, 182, 191
 oncology drugs, preclinical safety evaluation,
 575–576
 preclinical safety evaluation, 60–61
 monoclonal antibodies, 594–599
 protein scaffold therapeutics assessment,
 636–638
 relevant species criteria
 receptor presence and distribution, 288
 transcript profiling, 196–197
 reproductive/developmental toxicity testing
 limited species cross-reactivity, 361
 monoclonal antibodies, 362–365
 tissue cross-reactivity assay, monoclonal
 antibodies
 animal tissue, 216, 217, 232–233
 antibody-dependent cell-mediated cytotoxicity,
 248, 251
 assay control, 218
 background staining, 226
 CDR-mediated specific staining, 224
 clinical plasma levels, 250
 clinical significance, 278
 concentration selection, 223
 context for, 230–231
 epitope stability, 220, 223
 human tissue, 216–218, 231
 human vs. animal tissue, 216–218
 immune complex disease, 236–237
 isotope control antibody, 217
 microarray properties, 203
 non-CDR-mediated specific staining, 224, 232
 positive and negative controls, 194, 218
 preparation methods, 240
 scoring, 207, 226
 staining control, 218
 staining methods, 219, 221
 staining pattern characteristics, 225, 227
 test article affinity, 227
 test article forms, 227, 231

- tissue and staining adequacy, 217, 222
- valence, 234, 237
- Current good manufacturing practices (cGMPs), comparability guidelines, manufacturing changes, 171
- Cyclosporin A (CyA), carcinogenicity studies, 402
- Cynomolgus monkeys
 - reproductive/developmental toxicity testing in, 380–382
 - embryofetal development studies, 389, 391
 - fertility and embryonic development criteria, 383
 - reproductive failure, 390–392
 - toxicity studies, pharmacological activity, 345
- Cytokine release syndrome, immunotoxin evaluation, 661
- Cytokines
 - autoimmunity, 486–492
 - carcinogenicity studies, 460–461
 - ex vivo biologic effect, relevant species criteria, 188–189
 - first-in-human (FIH) trials, dose estimations, 980, 984
 - immunomodulatory biopharmaceuticals, atypical tumor promoters, 606–610
 - immunotoxicity testing, nonhuman primates, 350–353
 - pharmacodynamics studies, species specificity, 280, 282
 - safety pharmacology guidelines, 311–316
 - predictive safety biomarkers, inflammation and immune response studies, 321, 323
 - in vivo pharmacodynamics, relevant species criteria, 107
- Cytosolic transport, clearance mechanisms, 262
- Cytotoxicity, immunotoxin evaluation, 649, 654
- Daclizumab
 - carcinogenicity studies, 422
 - toxicity testing, 965
- Darpoietin alpha, carcinogenicity studies, 458
- Decentralized procedure (DCP), marketing authorization applications (EU), 75
- Dermagraft®, development of, 804
- Devices. *See* Medical devices
- Differentiation stability, neo-organ development, cell sources, 810
- Direct immunohistochemical staining, tissue cross-reactivity assay, 219–220
- Directive 65/65/EEC, pharmaceutical legislation and regulation, 70–71
- Directive 2001/83/EC, pharmaceutical legislation and regulation, 71
- Disease, animal models of, preclinical safety evaluation
 - abnormal kinetic behavior of compound, 293
 - hyperlipidemia, 298
 - immunogenicity, 303–304
 - indications for, 412
 - overview, 296, 307
- translational research, humanized models, 296–297
- undesirable progression evaluation, 302, 304
- Disposition mechanisms, pharmacokinetics assays, relevant species criteria, 285
- DNA damage
 - carcinogenicity studies, 457
 - genotoxicity studies
 - peptides, 502, 506
 - preclinical safety evaluation, 52
 - oligonucleotide genotoxicity studies, 546–550
- DNA vaccines
 - gene therapy products, 713
 - viral vaccine development, 683–684
- Dog studies, design and cost estimates, cardiovascular function assessment, 505, 558, 674
- Dornase alpha, carcinogenicity studies, 454
- Dose escalation studies
 - first-in-human (FIH) trials, 979
 - preclinical safety evaluations, rodents/nonrodents, 182, 314
- Dose-exposure relationships, safety pharmacology testing, 316
- Dose selection and administration
 - preclinical safety evaluation, 60–61
 - analysis costs, 904
 - design criteria, 918–925
 - maximum tolerated dose determination, 913, 918
 - no observed adverse effect level determination, 913, 919
 - protein scaffold therapeutics assessment, 633–648
- Double-stranded oligonucleotides
 - basic properties, 541
 - RNA-siRNA structures, 540–541
 - pharmacokinetics, 541–545
- Draize scores, preclinical safety evaluations, 903
- Drug discovery and development
 - drug properties and development program
 - design, 573, 613
 - monoclonal antibodies, tissue cross-reactivity assays, 230, 232
 - oncology drugs, preclinical safety evaluation, 575–576
 - preclinical development programs
 - clinical development plan, 131–132
 - critical decision making, 146–148
 - essential components for, 135–136
 - general assumptions, 131
 - integrated plans, 144–145
 - phase 1 supports, 132, 134
 - phase 2 supports, 148
 - phase 3 supports, 148
 - specific assumptions, 119, 253
 - therapeutic target, mechanism of action, and clinical indication, 131–132
 - traditional development plans, 135, 144
- Drug exposure evaluation, immunotoxins, 658–659
- Durability/longevity studies, neo-organ products, 824

- E3-Leiden variant gene, animal disease models, 301, 306
- Early embryonic development, reproductive/developmental toxicity testing, nonhuman primates, 382–383
- Efalizumab
 pharmacodynamics studies, species specificity, 277–278
 reproductive/developmental toxicity testing, 358, 361
 species specificity, 277–288
 toxicity testing, 965
- Effector function, Fc receptors, monoclonal antibody binding, 589, 592
- Elaprase, toxicity testing, 938
- Electrophysiological studies, Japanese points-to-consider documents, *in vitro* testing, 104
- Elitek®, toxicity testing, 938
- Elspar, toxicity testing, 939
- Embryofetal development studies
 design and cost estimates
 in rabbits, 854, 875, 934
 in rats, 854, 881, 890
 oncology drugs, preclinical safety evaluation, 580, 584
 reproductive/developmental toxicity testing, 371, 375
 nonhuman primates, 384, 389
- Endocrine system toxicity studies, oligonucleotide therapeutics, 563, 565
- End-organ toxicities
 neo-organ product testing, 815, 822
 safety pharmacology studies, 324–326
- Endothelial cells, immunoglobulin G clearance, 246, 248
 glomerular capillary endothelium, 256
- Endothelial progenitor cells (EPCs)
 cell-based therapies, 757
 neo-organ development, 823
- Endotoxin levels, preclinical safety assessments, bioburden testing of, 917
- Enfuvirtide, chronic toxicity studies, 503
- Environmental impact assessment
 biopharmaceutical production methods
 current technologies, 517
 host systems, 21, 27
 categorical exclusions, 33
 cellular systems manufacturing, 28
 comparability criteria
 manufacturing revisions, 32–33
 new technologies and, 107
 recombinant proteins, 26–28
 release criteria, 32
 transgenic animal manufacturing, 27–33
- Enzyme-linked immunoassay (ELISA), immunogenicity risk assays, 676
- Enzyme replacement therapies (ERT)
 administration techniques, 521–522
 basic principles, 517–518
 carcinogenicity studies, 462
 current technologies, 523–524
 future research issues, 533
 historical background, 518–520
 LSD pathophysiology, 518–520, 522–523
 LSD therapies, 520
 therapeutic models, 521
 regulatory issues, 524–534
 acid sphingomyelinase, 532–533
 Aldurazyme®, 530–531
 Cerezyme®, 526–528
 Fabrazyme®, 528–529
 Myozyme®, 531–532
 Epicel®, toxicity studies, 939
- Epidermal growth factor (EGF), *in silico* analysis, microarray data, 202–204
- Epidermal growth factor receptor (EGFR), reproductive/developmental toxicity testing, 370
- Epithelial tissue
 cross-reactivity assay pattern classifications, 227–230
 immunoglobulin G clearance mechanisms
 cytosolic transport, 262
 polymeric immunoglobulin A receptor, 254–256
- Epitope stability
 monoclonal antibody tissue cross-reactivity assay, 223
 clinical applications, 232
 pharmacodynamics studies, 283
 reproductive/developmental toxicity testing, monoclonal antibodies, 362–370
- Epogen®/Procrit®, toxicity studies, 940
- Eptifibatide, chronic toxicity studies, 508–509
- Equivalence, defined, 163
- Equivalent surface area dosage conversion factors, preclinical safety assessments, 919
- ERK protein, *ex vivo* biologic effect, signaling assays, 188–191
- Erythrocyte CR1, immunoglobulin G clearance mechanisms, 262
- Erythropoiesis stimulating agents, carcinogenicity studies, *in vitro* testing, 425–426
- Erythropoietin, species specificity, 282
- Establishment Inspection Report (EIR), good laboratory practice requirements, 836
- Etanercept
 carcinogenicity studies, 427
 hypersensitivity reactions, preclinical evaluation, 493–494
 reproductive/developmental toxicity testing, 364–370
 toxicity studies, 916
- European Commission (EC)
 cell-based therapies guidelines, 753–757
 good laboratory practice requirements and practices
 compliance requirements, 837–838
 history and scope, 832
 Sixth Framework Programme (FP6), carcinogenicity studies, 403–404

- structure and function, 70
- European Court of Justice, structure and function, 71
- European Economic Area (EEA), pharmaceutical legislation and regulation in, 72
- European Medicines Agency (EMA)
 - biogenerics regulations, 164–165
 - centralized procedure (CP), marketing authorization applications, 76–77
 - comparability guidelines, 166–167
 - first-in-human (FIH) trials guidelines, 975
 - gene therapy product regulation, 718–719
 - oligonucleotide genotoxicity studies, 548–551
 - reproductive/developmental toxicity testing, 358–359
 - structure and activities, 72–75
- European Parliament, structure and function, 70
- European Public Assessment Reports (EPARs), animal disease models, 300–302
- European Union (EU)
 - biopharmaceuticals in
 - approval requirements, 14–15
 - definitions, 11–12
 - marketing and postapproval requirements, 15–16
 - regulations, 12–13
 - research and development requirements, 13–14
 - cell-based therapies guidelines, 756–757
 - drug regulatory framework, 71–79
 - clinical trial authorizations, 77–78
 - European Medicines Agency, 72–75
 - marketing authorization applications, 75–78
 - pharmaceutical legislation and regulation, 71–72
 - scientific advice, 78–79
 - good laboratory practice requirements and practices
 - compliance requirements, 837–838
 - history and scope, 832
- International Conference on Harmonization (ICH) S6 implementation, 67–68, 79–89
 - chronic toxicity studies, 88
 - comparability testing, 88
 - guideline applications, 81–83
 - high-risk compounds criteria, 83–86
 - primate supply and use in animal modeling, 86–88
 - regulatory guidance activities, 79–81
 - origins of, 70–71
 - region-specific regulatory guidance in, 79–82
- Exaggerated pharmacology
 - animal disease models, 301
 - oligonucleotide therapeutics, hybridization-dependent toxicities, 545–546
 - preclinical safety evaluation
 - dose selection, schedule, duration, and response, 59–60
 - species selection criteria ad, 54–55
 - reproductive/developmental toxicity testing, 371–376
- Exocrine pancreatic insufficiency (EPI), enzyme replacement therapy, 517–518
- Exotoxin A (ETA)
 - mechanism of action, 653
 - preclinical safety assessment, 652–653
- Expert Scientific Group (ESG), high-risk compound evaluations, 83–86
- Exposure data
 - cell-based therapies, 767–768
 - U. S. points-to-consider documents, 118
- Exposure-response relationship, safety pharmacology testing, 316
- Expression systems, biopharmaceutical production, 23–27
- Extracellular matrices, stem cell transplants, preclinical safety evaluation, 764–765
- Ex vivo activated mononuclear leukocytes, cell-based therapies, 757–758
- Ex vivo biologic effect
 - manipulated autologous structural cells, 753–754
 - relevant species criteria, 184, 185–188
 - fixed endpoint assays, 189–190
 - signaling assays, 190–191
- Ex vivo/in vitro biopharmaceutical interaction, relevant species selection criteria, 194–196
- Ex vivo transduced cells, gene therapy toxicity studies, 734–737
- Fab antibody fragments
 - antibody classification and evolution, 210–214
 - immunoglobulin G biodistribution, intravascular-interstitial fluid compartment egress, 244–246
 - monoclonal antibody binding, 589–590
- Fabrazyme®
 - carcinogenicity, 442
 - development and regulation, 528–529
 - toxicity testing, 941
- Fabry disease, Fabrazyme® therapy for, 528–529
- Facilities evaluation, good laboratory practice requirements, preclinical development programs, 843–845
- Factor VIII
 - hypersensitivity, 489–491
 - preclinical safety evaluation, 669
- Factor IX
 - evolution of, 669–670
 - hypersensitivity reactions, 489–491
- Factor XIII, first-in-human (FIH) trials guidelines, transition to clinical trials, 974–975
- Factor H inhibition, phosphorothioate oligonucleotide acute toxicity, 554–556
- Failure analysis, neo-organ products, 822–824
- Fc receptors
 - antibody mediation with, 214–215
 - immunoglobulin G clearance mechanisms, 242–243
 - Fc₁RI receptor, 248–249
 - Fc₁R2 receptor, 249–250

- Fc receptors (*cont'd*)
 Fc_γR1II receptor, 250
 Fc_γR1 polymorphisms, 251–252
 human, mouse, and rabbit molecular determinants, 250–251
 liver tissue, 259–260
 neonatal Fc receptor (FcRn), 242–243, 253–254
 placenta and uterus, 258
 skin tissue, 259
 monoclonal antibody binding, 589–590
- Fertility studies
 design and cost estimates, 851, 876–877
 reproductive/developmental toxicity testing, 371–375
 nonhuman primates, 382–385
- Fialuridine (FIAU), pharmacodynamics, relevant species criteria, 279
- Filgrastim
 carcinogenicity studies, 437
 toxicity testing, 911
- First-in-human (FIH) trials
 cell-based therapies guidelines, 774–775
 safe starting dose, biopharmaceuticals
 calculation protocols, 975–978
 dose escalation/top dose limits, 982
 future research issues, 982–983
 overview, 971–972
 post-phase I calculations, 982
 preclinical-to-clinical dosing transition, 974–975
 protein therapeutics, estimation examples, 978–981
 protein therapeutics, human equivalent dose calculations, 978–979
 safety profiles, 972–973
- Fixed endpoint assays, ex vivo biologic effect, relevant species criteria, 189–190
- FK778 compound, predictive failure, animal toxicology studies, 329
- Flow cytometry methods
 ex vivo/in vitro biopharmaceutical interaction, relevant species selection criteria, 194–196
 immunotoxicity testing, 349–353
 safety pharmacology studies, 328
- Fluorescein isothiocyanate (FITC) testing, receptor presence and distribution, relevant species criteria, 191–192
- Food, Drug and Cosmetics (FD&C) Act
 biologics, 164–165
 generic drugs and bioequivalence, 163–164
 good laboratory practice requirements and practices, 832–833
- Food and Drug Administration (FDA) (U.S.)
 blood product evaluation guidelines, 671
 hemoglobin-based oxygen carriers, 672–673
 immunoglobulins, 675–676
 carcinogenicity testing, peptide hormones, 509–513
 cell-based therapies guidelines, 753–757
 pre-IND submission guidelines, 773–774
- combination biologic/device products
 definitions, 784–786
 regulatory guidelines, 800, 804
 comparability guidelines, 165–167
 non-regulatory applications, 173–174
 generic drug requirements, 163–164
 gene therapy product regulation, 719–720
 GMPs for the twenty-first century initiative, 162
 good laboratory practice requirements
 common U.S.-international elements in, 833–835
 history and scope, 832–833
 laboratory compliance regulations, 835–836
 OECD regulation comparisons, 838–839
 overview of, 829–831
 regulations and compliance requirements, 835–836
 ICH S6 implementation, 111–113
 neo-organ development guidelines, 799–808
 preclinical safety assessment design, 913–914
 reproductive/developmental toxicity studies guidelines, 358–359
- Form follows function (FFF), oncology drugs, preclinical safety evaluation, 576–584
- Formulation changes, biologics, preclinical development programs, 153–156
- Formyl peptide receptor (FPR), chronic toxicity studies, 509
- Functionality assessment, combination biologic/device products, 783–787
- Fusion proteins
 first-in-human (FIH) trials, dose estimations, 978
 reproductive/developmental toxicity testing, monoclonal antibodies, 362–370
- GAA knockout mice, Myozyme® development and regulation, 531–532
- α-Galactosidase, development, 528
- Gamma-delta T cell populations, animal toxicology studies, 330
- Gastrointestinal safety pharmacology, oligonucleotide therapeutics, 553
- Gaucher disease, Cerezyme® therapy for, 520–521, 526–527
- Generic drugs
 bioequivalence and, 163–164
 biologics, 164–165
- Gene therapy
 adjuvants with, 727
 carcinogenicity studies, 409, 421, 459
 coagulation disorders, 677, 680
 defined, 715
 FDA/recombinant DNA Advisory Committee roles in, 719
 gene transfer mode, 715
 historical background, 716–717
 later stage product development, 742
 preclinical safety evaluation, 730, 742
 future research issues, 744
 overview, 624, 707, 807

- preventive and plasmid DNA vaccines vs., 716
- vectors used in, 720, 721, 723, 725
 - adeno-associated viral vectors, 723–724
 - adenoviral vectors, 722–723
 - nonviral vectors, 720–721
 - replication-competent oncolytic vectors, 727
 - replication-deficient viral vectors, 722
 - retroviral and lentiviral vectors, 724–726
 - worldwide regulation, 718
- Gene transfer
 - gene therapy development, 715–716
 - good laboratory practice requirements for
 - research on, 838–839
- Genomics, biopharmaceutical production and, 22
- Genotoxicity studies
 - biopharmaceuticals, 337–338, 965
 - cell-based therapies, 755, 757, 761
 - immunotoxins, 661, 663
 - Japanese points-to-consider documents, 105, 107
 - oligonucleotide therapeutics, 547, 549
 - oncology drugs, preclinical safety evaluation, 583–584
 - peptides, 506–509
 - preclinical safety evaluation guidelines, 63
 - U. S. points-to-consider documents, 103, 107
 - viral vaccine development, 698, 700
- Global regulations and compliance, good
 - laboratory practices, 837
- Glomerular capillary endothelium,
 - immunoglobulin G clearance
 - mechanisms, 256
- Glomerular filtration, pharmacokinetics studies, 542
- Glucagons, toxicity testing, 911, 964
- Glycosylated protein biopharmaceuticals,
 - predictive failure, animal toxicology
 - studies, 329
- Good laboratory practice (GLP)
 - basic elements of, 833
 - cell-based therapies, toxicity studies, 761
 - compliance strategies, pragmatic approach, 839
 - FDA vs. OECD regulations, 838
 - future research and regulatory issues, 788
 - gene therapy safety evaluation, 739
 - global regulations and compliance, 837
 - history and scope, 832
 - ICH S7A safety pharmacology guidelines, 312
 - immunotoxicity testing, 350
 - preclinical safety evaluation
 - cost estimates and design criteria, 821
 - site selection, 839
 - regulatory background, 829
 - U.S. regulations and compliance, 830, 835, 837
- Good manufacturing practices (GMPs), preclinical
 - testing and production process, 822
- Granulocyte colony stimulating factor (G-CSF),
 - pharmacodynamics, relevant species
 - criteria, 279
- Growth factors
 - carcinogenicity studies, 403, 408
 - becaplermin, 460–461
 - palifermin, 461
 - oncology drugs, 576, 578
 - safety pharmacology guidelines, 314
 - toxicity testing, 911, 964
- Growth hormones, carcinogenicity studies, 457
- Hazard analysis, immunomodulatory
 - biopharmaceuticals, 624
- Health and Environmental Sciences Institute (HESI), preclinical carcinogenic potential
 - assessment, 421
- Hematologic toxicity, oligonucleotide therapeutics, 560
- Hematopoietic stem cells (HSCs), cell-based
 - therapies, 759, 761
- Hemoglobin-based oxygen carriers (HBOCs),
 - preclinical safety evaluation, 671
- Hemophilia
 - blood products, preclinical evaluation
 - guidelines, 672
 - recombinant DNA, coagulation therapies, 676
- Hepatic tissue, oligonucleotide toxicity effects, 562
- Hepatitis B vaccine (HBV), recombinant protein
 - technology, 686
- Herpes simplex viral (HSV) vectors, gene therapy
 - products, 726
- Heterologous cells, neo-organ development, 808
- HGB-30 synthetic peptide, viral vaccine
 - development, 702, 704
- Highest dose selection
 - ICH S6 protocols, Japanese guidelines for, 96
 - Japanese points-to-consider documents on, 103
- High-risk compounds
 - biologic/drug preclinical development programs, 157
 - EU regulatory guidance concerning, 79
- Histopathology abbreviations and codes,
 - preclinical safety assessments, 928
- Homologous proteins
 - biologics, preclinical development programs, 151, 153
 - immunomodulatory biopharmaceuticals, in vivo
 - testing, 624
 - neo-organ development, 810
 - protein scaffold therapeutics assessment, 640–641
 - in silico analysis, relevant species criteria, 199–200
- Host systems
 - biopharmaceutical production and, 23–25
 - immunogenicity risk assessment, 394
 - immunomodulatory biopharmaceuticals, atypical
 - tumor promoters, 607
 - resistance studies, integrated preclinical-clinical
 - immunotoxicity assessments, 325
 - tumor host-resistance models, carcinogenicity
 - studies, 421
 - viral vaccine integration, 688

- Human antihuman antibody (HAHA)
antibody-coated stent devices, 796
preclinical safety evaluation, 593
- Human anti-murine antibodies (HAMA),
preclinical safety evaluation, 593
- Human cell-based therapies. *See* Cell-based therapies
- Human cells, tissues, and cellular and tissue-based products (HCT/Ps), cell-based therapies guidelines, 756
- Human embryonic kidney (HEK293) cells,
cardiovascular function testing, design and cost estimates with, 855
- Human embryonic stem cells (hESC), cell-based therapies, 761
- Human equivalent dose (HED), first-in-human (FIH) trials guidelines
protein therapeutics, 978
starting dose calculations, 977
- Human ether-a-go-go (hERG) gene
cardiovascular function testing, design and cost estimates with, 855, 890–891
oligonucleotide safety pharmacology, 552
protein scaffold therapeutics assessment, 646
QT liability testing and, 316
- Human Fertilisation and Embryology (HFE) Act,
cell-based therapies guidelines, 756
- Human immunodeficiency virus type 1 (HIV-1)
gene therapy products, lentiviral vectors, 725
immunomodulatory biopharmaceuticals, 601
viral vaccine development, 702
- Humanized animal disease models
monoclonal antibodies, 592
translational research, 296–297
- Human pharmacological activity
carcinogenicity studies, 403, 408
monoclonal antibodies, 591
oligonucleotide immunotoxicity, 567–568
reproductive/developmental toxicity testing,
monoclonal antibodies, 360, 364, 371
toxicity testing and, 348–349
- Human protein biopharmaceuticals
basic properties of, 99
Japanese points-to-consider documents, 103
- Human tissue
cross-reactivity assay, monoclonal antibodies,
216, 236
animal tissue vs., 216
antibody-dependent cell-mediated cytotoxicity,
215, 248
immune complex disease, 237
valence, 234
immunoglobulin G clearance mechanisms,
molecular determinants, 252
- Hybridization-dependent toxicities, oligonucleotide therapeutics, 544
- Hybridization-independent toxicities,
oligonucleotide therapeutics, 547
- Hyperlipidemia, transgenic humanized mouse models, 299
- Hypersensitivity reactions
clinical assessment, 474
cross-reactivity assay, monoclonal antibodies,
233–234
future research issues, 494
preclinical biopharmaceutical evaluation,
493–494
regulatory guidance, 491
- Imiglucerase. *See* Cerezyme®
- Immune complex disease
blood products therapies, preclinical evaluation guidelines, 674
immunoglobulin G clearance mechanisms,
erythrocyte CR1 clearance, 261
monoclonal antibodies, 236–237
toxicology studies, biopharmaceuticals,
predictive safety biomarkers, 321, 323
- Immune system, reproductive/developmental toxicity testing, nonhuman primates, pre/postnatal development, 392
- Immunogenicity studies
animal disease models, 304
antibody response, 480–481
blood products, preclinical evaluation, 676
comparability testing and, 167
design and cost estimates, 854, 873
immunotoxin development, 650
preclinical safety evaluation, 657
murine monoclonal antibodies, 590–591
pharmacokinetics assays, relevant species
criteria, 286–288
pharmacokinetics/toxicokinetics studies, 925
preclinical safety evaluation, 60
therapeutic proteins, risk assessment
antibody response, 480
assay strategies, 483
B cell tolerance, 478
foreign protein activation, 479
grading of consequences, 477
immune response, probability prediction,
477
mixed immune reactions, 480–481
risk definition, 476
toxicity studies, rodents/nonrodents
pharmacological activity, 345
U.S. ICH S6 implementation, 117
viral vaccine development and, 696
- Immunoglobulin A (IgA), antibody classification and evolution, 210
- Immunoglobulin D (IgD), antibody classification and evolution, 210
- Immunoglobulin E (IgE), antibody classification and evolution, 210
- Immunoglobulin G (IgG)
antibody classification and evolution, 210,
242–243
clearance mechanisms, 252
breast, 257
colon, 261

- cytosolic transport, epithelial/mesothelial tissue, 262
- erythrocyte CR1 clearance, 262
- FcRn transport, 253
- kidney, 256
- liver, 259
- lungs, 258
- lymphatic clearance, 248
- mononuclear phagocyte system/endothelial cell clearance, 248
- ovary, 257
- placenta and uterus, 258
- plasma clearance and tissue catabolism, 252
- plgR on epithelial cells, 256
- salivary glands, 260
- seminal fluid, 258
- skin, 259
- thyroid, 261
- tissue-specific transport, 241, 245–246
- endogenous biodistribution, 241–244
 - in interstitial fluid compartment, 241, 244, 247
 - intravascular into interstitial egress, 241, 244, 247
 - tissue-specific transport/uptake barriers, 241, 246
- monoclonal antibodies
 - structure and function, 588
 - tissue cross-reactivity assay, 210
 - antibody-dependent cell-mediated cytotoxicity, 210, 214, 248, 251
 - receptor presence and distribution, relevant species criteria, 181, 184, 191
- Immunoglobulin M (IgM), antibody classification and evolution, 210, 211
- Immunoglobulins
 - antibody classification and evolution, 210
 - blood products therapies, preclinical evaluation guidelines, 669, 670–672, 677
- Immunohistochemistry. *See also* Tissue cross-reactivity assay
 - recombinant proteins, 32–33
 - tissue cross-reactivity assay, staining methods, 210
- Immunological tolerance, viral vaccine evaluation, 687–688
- Immunomodulatory biopharmaceuticals (IMBPs)
 - carcinogenicity studies, 403, 408–409, 421
 - abatacept, 427
 - anakinra, 427, 443, 445, 456
 - clinical trials, 601
 - future research issues, 613, 637
 - overview, 537, 545
 - potential tumor progression, 609
 - promoter identification and characterization models, 610, 612, 614, 617, 619
 - in vitro mechanisms, 611
 - in vivo systems, 611
 - risk assessment and classification, 621–624
 - testing protocols, 602
 - tumor promotion, 605, 607–611
 - viral vaccine development and, 691, 697
- Immunophenotyping, integrated preclinical-clinical immunotoxicity assessments, 325
- Immunostimulatory oligonucleotides
 - basic properties, 540–541
 - chemistry, 537, 539, 540
- Immunosuppression
 - animal disease models, 301, 304
 - safety pharmacology studies
 - integrated preclinical-clinical techniques, 327–328
 - predictive carcinogenicity, 509–513
 - predictive failure, animal toxicology studies, 328, 330
- Immunotoxicity studies
 - biopharmaceuticals, 966
 - design and cost estimates, in monkeys, 851, 855
 - general guidelines, 349–353
 - immunomodulatory biopharmaceuticals, tumor promoters and progressors, 606–607, 609
 - immunotoxins, 661
 - oligonucleotide therapeutics, 560, 565–567
 - safety pharmacology techniques, integrated preclinical-clinical immunotoxicity assessments, 324–325
 - U. S. points-to-consider documents, 114
- Immunotoxins
 - developmental progress assessment, 660
 - mechanism of action, 653
 - preclinical safety evaluation, 649
 - animal model selection and administration route, 655–656
 - carcinogenicity, 661
 - drug exposure evaluation, 658
 - genotoxicity, 661
 - ICH S6 guidelines, 653
 - immunogenicity and toxicity, 651–652, 662–663
 - immunotoxicity studies, 660
 - repeated-dose toxicology studies, 656, 660
 - reproductive/developmental toxicity, 660, 662
 - safety pharmacology, 660
 - single-dose toxicology studies, 656
 - rational design, 650–651
 - specificity, toxicity, and serum stability, 654–655
 - target antigens, 649–650
 - toxin properties, 650
 - VB4-845, 652–653
- Independent national procedure, marketing authorization applications (EU), 75
- Indirect immunohistochemical staining, tissue cross-reactivity assay, 219–220
- Infergen®, toxicity testing, 944
- Inflammation, toxicology studies,
 - biopharmaceuticals, predictive safety biomarkers, 321
- Infliximab®
 - carcinogenicity studies, 427
 - reproductive/developmental toxicity testing, 361–364
 - TNF- α neutralization, 213–214
 - toxicity testing, 954

- INFUSE® Bone Graft/LT-CAGE® lumbar tapered fusion device, development, 804–805
- Initial evaluation test protocols, neo-organ products, 815–816
- In silico analysis, relevant species criteria, 184, 199
microarray data, 200
sequence homology, target protein, 199–200
- Insulin analogues
carcinogenicity studies, 457, 459–460
in vitro studies, 510
toxicity testing, 964
- Insulin aspart
carcinogenicity studies, 457
toxicity testing, 954
- Insulin detemir, carcinogenicity studies, 437
- Insulinalgargine, carcinogenicity studies, 457
- Insulin exubera
carcinogenicity studies, 448
toxicity testing, 954
- Insulin glulisine
carcinogenicity studies, 446–447
toxicity studies, 945
- Insulin-like growth factor (IGF), carcinogenicity studies, 458–459
- Integrated preclinical development plans, drugs and biologics, support for, 144
- Integration assays, viral vaccine development, 701, 706
- Interendothelial-associated immunoglobulin G
biodistribution, intravascular-interstitial fluid compartment egress, 246
- Interferons
autoimmunity, 488–489
carcinogenicity studies, 457
historical development of, 669
pharmacodynamics studies, species specificity, 279
reproductive/developmental toxicity testing, limited species cross-reactivity, type I interferons, 361
toxicity testing, 964
- Interleukins
immunomodulatory biopharmaceuticals, atypical tumor promoters, 609
toxicity testing, 964
- International Conference on Harmonization (ICH)
comparability guidelines, 166–168
European Union (EU) implementation of ICH S6, 67–68, 79–88
chronic toxicity studies, 88
comparability testing, 88
guideline applications, 81–83
high-risk compounds criteria, 83–85
primate supply and use in animal modeling, 86
regulatory guidance activities, 79–81
Expert Working Group on Safety, preclinical carcinogenic potential assessment, 421
first-in-human (FIH) trials guidelines, 975
future research issues, 60–61
gene therapy product regulation, 719–720
- ICH M3 guidelines
drug and biologics development program design, 128–130
toxicity studies, rodents/nonrodents pharmacological activity, 344–345
- ICH Q5D guidelines, cell line biopharmaceutical production, 410
- ICH Q5E guidelines, comparability testing, 172
- ICH S2B guidelines, genotoxicity testing, 337
- ICH S5A guidelines, reproductive/developmental toxicity studies guidelines, 358
- ICH S5(R2) guidelines, gene therapy safety evaluation, 741
- ICH S6 (case-by-case approach)
animal disease models, 294, 297
autoimmunity and hypersensitivity, 487–488, 491
blood product evaluation guidelines, 669–672
carcinogenicity studies of biopharmaceuticals, 412–420, 509, 512
drug and biologics development program design, 130
enzyme replacement therapies, 525–527
evolution of, 80
genotoxicity testing, 506
immunotoxin evaluation, 654–661
implementation in EU, 67–88
monoclonal antibody guidelines, 208–210, 593–594, 597
oncology drugs, preclinical safety evaluation, 579
peptide toxicity assessment, 502–512
pharmacokinetics/toxicokinetics studies, 925
preclinical safety assessment design, 914
quality controls, preclinical safety assessments, 916
relevant species criteria, 181–182
reproductive/developmental toxicity studies guidelines, 358–360
species selection criteria, 914
- ICH S6, Japanese implementation of, 93–104, 107–109
ADME studies, 98
animal species selection, 95
antibodies, 102
biopharmaceutical categories, 96
carcinogenicity studies, 105–106
conventional biologics, 103
electrophysiology, in vitro studies, 108
future points-to-consider documents, 94
genotoxicity studies, 106–107
high dose selection, 94
JPMA questionnaire survey, 95
metabolism studies, 102, 104
non-protein-peptide-based biologics, 103
peptide-based biologics, 102
points-to-consider document, 99–100
protein-based biologics, 100–102
repeat-dose toxicity studies, 104
reproductive/developmental toxicity studies, 105
single-dose toxicity studies, 104

- toxicological effects and pharmacological action, 103, 105
- in vitro studies, 98
- ICH S7A safety pharmacology guidelines
 - biopharmaceuticals, 312
 - Fabrazyme® therapy, 534
 - small-molecule core battery approach, 312
- ICH S7B in vitro safety pharmacology, 58
 - electrophysiological studies, 107
 - QT liability, preclinical evaluation, 317–318
- ICH S8 guidelines
 - immunotoxicity testing, 345, 350
 - integrated preclinical-clinical immunotoxicity assessments, 324–325
- preclinical safety evaluation
 - animal models guidelines, 51–55
 - design and cost guidelines documentation, 904
 - dose selection, schedule, duration, and response, 59, 61
 - reproductive/developmental toxicity studies, overview, 379–382
 - safety evaluation history of, 47–49
 - safety pharmacology guidelines, oligonucleotide therapeutics, 551–554
 - timing of preclinical studies issues, 108
- United States implementation of ICH S6
 - administration/dose selection, 115–116
 - animal species selection, 115–116
 - carcinogenicity studies, 120
 - exposure limits, 118–119
 - General Principles, 115
 - genotoxicity studies, 119
 - historical perspective, 113
 - immunogenicity, 115, 117–118
 - immunotoxicity, 119
 - local tolerance, 120
 - regulatory issues, 112
 - repeat-dose studies, 118–119
 - reproductive/developmental studies, 119
 - safety pharmacology/single-dose studies, 118
- International Life Sciences Institute (ILSI), preclinical carcinogenic potential assessment, 421
- International Programme on Chemical Safety (IPCS), carcinogenicity studies, 403
- Interspecies scaling, first-in-human (FIH) trials, human equivalent dose calculations, 977–979
- Interstitial fluid, immunoglobulin G
 - biodistribution
 - in-compartment distribution, 247–248
 - intravascular fluid compartment egress to, 244
- Intra-species variation, relevant species criteria, pharmacodynamics studies, 283
- Intravascular fluid compartment, immunoglobulin G
 - biodistribution, egress to interstitial fluid compartment, 244
- Intravenous infusions, dose volume/rates, preclinical safety evaluations, design specifications, 923
- Intrinsic toxicity, preclinical safety evaluation, species selection criteria ad, 54–55
- Intron A®, toxicity testing, 944
- Investigational medicinal product (IMP), clinical trial authorizations, 77
- In vitro testing
 - carcinogenicity studies
 - cell proliferation, 423–425
 - peptide hormones, 511–513
 - chromosomal aberration, design and cost estimates, 852, 897–898
 - immunomodulatory biopharmaceuticals, 610–612
 - Japanese biopharmaceutical studies, 94
 - Japanese points-to-consider documents, electrophysiological studies, 104
 - neo-organ products, design criteria, 819–821
 - oligonucleotide genotoxicity studies, 549–551
 - preclinical safety evaluation, 61
 - monoclonal antibodies, 594–597
 - relevant species criteria, 184, 196–197
 - binding assays, 194–195
 - ex vivo/in vitro biopharmaceutical interaction, 194–195
- In vivo testing
 - cell-based therapies, 759, 761
 - toxicity studies, 770–771
 - immunomodulatory biopharmaceuticals, 612–621
 - Japanese biopharmaceutical studies, 96–98
 - neo-organ products, design criteria, 817–819
 - oligonucleotide genotoxicity studies, 549–551
 - pharmacodynamic effects, 185, 187
 - relevant species criteria, known targets, 184
- Inward rectifying potassium channel (i(Kr)), hERG encoding, QT liability testing, 317
- Irwin test, safety pharmacology, central nervous system effects, 321
- ISIS 2302, immunotoxicity studies, 567
- ISO 10993 device safety testing
 - combination biologic/device products, 795–796
 - neo-organ product testing, endpoint selection, 819
- Isotype control antibody, tissue cross-reactivity studies, 218
- Japan
 - biopharmaceuticals, 16–18
 - good laboratory practice requirements and practices, 837–838
- ICH S6 implementation in, 93–109
 - ADME studies, 99
 - animal species selection, 95
 - antibodies, 102
 - biopharmaceutical categories, 96
 - carcinogenicity studies, 105
 - conventional biologics, 103
 - electrophysiology, in vitro studies, 108
 - future points-to-consider documents, 105–107

- Japan (*cont'd*)
 genotoxicity studies, 106–107
 high dose selection, 94
 JPMA questionnaire survey, 95
 metabolism studies, 104
 non-protein-peptide-based biologics, 103
 peptide-based biologics, 102
 points-to-consider document, 99–107
 protein-based biologics, 100–102
 repeat-dose toxicity studies, 104–105
 reproductive/developmental toxicity studies, 105
 single-dose toxicity studies, 104
 toxicological effects and pharmacological action, 103–104
 in vitro studies, 98–99
 in vivo studies, 96–98
- JPMA questionnaire survey, ICH S6
 implementation in Japanese
 pharmaceutical companies, 95–99
- Kidney injury molecule-1 (KIM-1), as predictive
 biomarker, safety pharmacology studies,
 324–325
- Kidneys
 immunoglobulin G clearance mechanisms,
 256–257
 pharmacokinetics assays, relevant species
 criteria, 284–286
- Kinetic analysis, animal disease models, abnormal
 compound behavior, 303
- KLH (keyhole limpet hemocyanin), viral vaccine
 development, 703
- Knock-in animal models
 immunomodulatory biopharmaceuticals, in vivo
 testing, 615–621
 preclinical safety evaluation, 48–52
 safety pharmacology applications,
 biopharmaceuticals, 314–316
- Knock-out animal models
 acid sphingomyelinase development and
 regulation, 532–533
 biologics, preclinical development programs,
 151–153
 disease models, 296
 hypersensitivity reactions, preclinical evaluation,
 494
 immunomodulatory biopharmaceuticals, in vivo
 testing, 612–621
 Myozyme® therapy, 531
 preclinical safety evaluation, 53–57
 safety pharmacology applications,
 biopharmaceuticals, 314–316
 toxicity testing, 348–349
- Kupffer cell components, cross-reactivity assays,
 231
- Lantus® (insulin glargine), toxicity testing, 945
- Large molecular weight compounds, reproductive/
 developmental toxicity testing, 359–361,
 370–375
- Laronidase. *See* Aldurazyme®
- Lentiviral vectors, gene therapy products, 724–726
- Leukine®, toxicity testing, 946
- Leukocyte-associated immunoglobulin G
 biodistribution, intravascular-interstitial
 fluid compartment egress, 245–246
- Levenir, toxicity testing, 946
- Limulus amoebocyte lysate (LAL) test, preclinical
 safety assessments, quality evaluation, 917
- Liver tissue
 immunoglobulin G clearance mechanisms,
 259–261
 oligonucleotide toxicity effects, 562
- Local tolerance assessments
 cell-base therapies, 759–761
 U.S. points-to-consider documents, 120
- Long-QT syndrome (LQTS), safety pharmacology
 testing and, 317–318
- Lucentis™, toxicity testing, 947
- Lung tissue, immunoglobulin G clearance
 mechanisms, 258–259
- Lymphatic clearance, immunoglobulin G, 248
- Lymphocyte counts, in vivo pharmacodynamics,
 relevant species criteria, 186–187
- Lymphocyte function associated antigen 1 (LFA-
 1), species specificity, 281
- Lymphohistiocytic infiltrates, oligonucleotide
 subchronic/chronic toxicity, 559–560
- Lymphokine-activated killer (LAK) cells, cell-
 based therapies, 757–758
- Lymphoma mutagenesis, rodent studies, design
 and cost estimates, 852, 896
- Lymphoproliferative disorders, carcinogenicity
 studies, 405
- Lysosomal storage diseases (LSDs)
 enzyme replacement therapies, 520
 acid sphingomyelinase, 532–533
 Aldurazyme®, 530
 background, 518
 Cerezyme®, 526–528
 delivery systems, 521–522
 Fabrazyme®, 528–529
 models for, 521
 Myozyme®, 531
 future research issues, 533–534
 pathophysiology, 518–520, 522–523
- Macaques. *See also* Nonhuman primates (NHP)
 reproductive/developmental toxicity testing in,
 382
 fertility and embryonic development criteria,
 382–385
 toxicity studies, pharmacological activity, 345
- Macrophage/neutrophil functional assays,
 integrated preclinical-clinical
 immunotoxicity assessments, 326
- Magnetic resonance imaging (MRI), cell-based
 therapies exposure assessment, 768
- Malignancy variations, carcinogenicity studies,
 404–405

- Manipulated autologous structural (MAS) cells
 ex vivo manipulation, 758–759
 regulatory guidelines for, 754–757
- Mannose-6-phosphate (M6P)-mediated transport
 Cerezyme® development, 527–528
 enzyme replacement therapies, 521–522
- Manufacturing technologies
 biologics, preclinical development programs,
 153–155
 cellular systems, 27–28
 comparability testing
 alterations in current systems, 35–37
 general principles and practices, 168–171
 clinical considerations, 171–172
 immunogenicity, 173
 indications for, 169–170
 manufacturing changes, 170
 physicochemical characterization, 170
 preclinical considerations, 171
 new technologies, 37–39
 regulatory guidance
 EMEA guidelines, 166–167
 FDA guidelines, 165–167
 ICH guidelines, 166–168
 transgenic animals, 28–29
- Marketing approval, comparability testing
 following, 174–175
- Marketing Authorization Applications (MAAs),
 EU guidelines for, 75–77
- Marketing requirements, biopharmaceuticals
 in European Union, 15–16
 in United States, 9–10
- Marmosets. *See also* Nonhuman primates (NHP)
 protein scaffold therapeutics assessment,
 640–641
 reproductive/developmental toxicity testing in,
 382
 embryofetal development studies, 388–390
 toxicity studies, pharmacological activity,
 345–346
- Material production techniques, oncology drugs,
 preclinical safety evaluation, 581
- Maximum expected environmental concentration
 (MEEC), environmental assessment and,
 34–35
- Maximum recommended starting dose (MRSD),
 first-in-human (FIH) trials guidelines,
 975
- Maximum tolerated dose (MTD)
 combination biologic/device products, 793–794
 drugs and biologics preclinical development
 programs, 134–135
 first-in-human (FIH) trials guidelines, 973
 preclinical safety assessment design, 924–925
 protein scaffold therapeutics assessment,
 643–644
- Mecasermin, carcinogenicity studies, 452
- Mechanisms of action
 drugs and biologics preclinical development
 programs, 131–132
 relevant species criteria, in vivo
 pharmacodynamics, 185–188
- Medical devices
 combination biologic/device products
 antibody-coated stent example, 783
 basic properties, 784–788, 797–798
 biologic orientation assessment, 790
 functionality assessment, 786–787
 pharmacological/toxicological assessment, 792–795
 potential elution species, 791
 regulatory issues, 788, 797
 testing strategies, 789–792
 neo-organ development, regulatory guidelines,
 801–804
- Medical Device User Fee and Modernization Act
 (MDUFMA), neo-organ development,
 801–804
- Mesangium, immunoglobulin G clearance, 256
- Mesenchymal stem cells (MSCs), cell-based
 therapies, 760–761
- Mesothelium, immunoglobulin G clearance
 mechanisms, cytosolic transport, 262
- Metabolism studies
 Japanese points-to-consider documents, 103
 phosphorothioate oligonucleotide
 pharmacokinetics, 543–544
 protein scaffold therapeutics assessment,
 645–646
- Microarray analysis
 relevant species criteria, 200–203
 tissue cross-reactivity studies, 217
- Micronucleated polychromatic erythrocytes
 (MPCE), mouse bone marrow cells,
 design and cost issues, 852, 895–896
- Minimal anticipated biological effect level
 (MABEL)
 animal toxicity studies, predictive failure
 analysis, 329–331
 first-in-human (FIH) trials guidelines, 975
 human equivalent dose calculations, 978–979
 starting dose calculations, 977–978
 high-risk compound evaluations, 84
 preclinical safety evaluation, 60
- Minimal effective dose (MED), combination
 biologic/device products, 793–794
- Mitogenicity, peptides, 510–512
- Mixed modality paradigms, viral vaccine
 evaluation, 691, 705–706
- Molecular classes, oncology drugs, 575–576
- Molecular weight, pharmacokinetics assays,
 relevant species criteria, 284–286
- Monoclonal antibodies (mAbs)
 antibody-coated stents, 789
 antibody types and evolution, 210–213
 biological effects, 214–215
 carcinogenicity studies, preclinical
 biopharmaceutical evaluation, 403–409,
 421–454
 cross-reactivity studies, basic principles, 209–210
 future antibody development research, 597–598

- Monoclonal antibodies (mAbs) (*cont'd*)
 genotoxicity studies, 337
 historical background, 107
 immunoglobulin G clearance mechanisms,
 248–252
 breast, 257
 colon, 261
 cytosolic transport, epithelial/mesothelial tissue,
 262
 erythrocyte CR1 clearance, 262
 FcRn transport, 253–254
 kidney, 256–257
 liver, 259–260
 lungs, 258–259
 lymphatic clearance, 248
 mononuclear phagocyte system/endothelial cell
 clearance, 248–250
 ovary, 257
 placenta and uterus, 258
 plasma clearance and tissue catabolism, 252
 pIgR on epithelial cells, 254–256
 salivary glands, 260–261
 seminal fluid, 258
 skin, 259
 thyroid, 261
 tissue-specific transport, 252–262
 immunotoxicity testing, 353
 preclinical development programs, 593–597
 alternative plans for, 148–156
 cell line, manufacturing process, formulation, or
 administrative route changes, 153–156
 clinical development plan, 132–134
 critical decision making, 146–148
 design for, 128–130
 essential components for, 135–137
 general assumptions, 131
 integrated plans, 144–146
 limitations of, 183
 Phase 1 supports, 137–140
 Phase 2 supports, 140–142
 Phase 3 supports, 142–144
 planning guidelines, 158
 relevant species, absence of, 149–153
 specific assumptions, 134–135
 therapeutic target, mechanism of action, and
 clinical indication, 131–132
 traditional development plans, 135–148
 preclinical safety evaluation
 chimeric monoclonal antibodies, 592
 Fc binding, 589–590
 fully human monoclonal antibodies, 592–593
 fully murine monoclonal antibodies, 590–592
 humanized monoclonal antibodies, 592
 overview, 545–548
 relevant species criteria
 receptor presence and distribution, 192–193
 species specificity, 279–282
 in vitro binding, 196
 reproductive/developmental toxicity testing,
 362–370
 tissue cross-reactivity assay
 animal tissue, 216, 232–233
 antibody-dependent cell-mediated cytotoxicity,
 235–236
 assay control, 218
 background staining, 226
 CDR-mediated specific staining, 224
 clinical plasma levels, 222–223
 clinical significance, 231–232
 concentration selection, 223
 context for, 230–231
 epitope stability, 223
 human tissue, 216, 233–237
 human vs. animal tissue, 216–217
 immune complex disease, 236–237
 isotope control antibody, 218
 microarray properties, 217
 non-CDR-mediated specific staining, 224–225
 positive and negative controls, 218–219
 preparation methods, 217–218
 scoring, 226–227
 staining control, 218
 staining methods, 219–220
 staining pattern characteristics, 227–230
 test article affinity, 222
 test article forms, 220–222
 tissue and staining adequacy, 225–226
 valence, 234–235
 Mononuclear phagocytes
 ex vivo activated mononuclear leukocytes, cell-
 based therapies, 757–758
 immunoglobulin G clearance, 248–252
 oligonucleotide toxicity, 559–560
 Morpholinos
 basic properties, 540
 single-stranded oligomer pharmacokinetics, 544
 mRNA, oligonucleotide therapeutics, surrogate
 molecules, 547–548
 Mucopolysaccharidoses (MPSs1–7), lysosomal
 storage disease pathology, 518–520
 Murine monoclonal antibodies, preclinical safety
 evaluation, 590–592
 Muromonab
 CD3 molecule, carcinogenicity studies, 456
 immunogenicity, 590–591
 Mutual Recognition Procedure (MRP), marketing
 authorization applications (EU), 75–77
 MVI-HIVA components, viral vaccine
 development, 705–706
 MylotargTM
 evaluation of, 660–662
 toxicity testing, 945
 Myozyme®
 development and regulation of, 531–532
 lysosomal storage disease pathophysiology,
 522–523
 toxicity testing, 948
 N-acetyl-beta-D-glucosaminidase
 oligonucleotide toxicity and, 564–565

- as predictive biomarker, safety pharmacology studies, 324–325
- Naglazyme™, toxicity testing, 948
- Natalizumab
 - carcinogenicity studies, 445
 - immunotoxicity testing of, 352
 - reproductive/developmental toxicity testing, 362–370
 - toxicity testing, 964
- National Competent Authorities, structure and activities, 72–75
- National Institutes of Health (NIH), gene therapy product regulation, 719–720
- Natural killer cell activity assays
 - integrated preclinical-clinical immunotoxicity assessments, 324
 - oligonucleotide immunotoxicity, 567
- NCEs, safety pharmacology, peptides, 507–508
- Needle sizes, preclinical safety evaluations, design specification, 922
- Negative tissue control, tissue cross-reactivity assay, 218–219
- Neonatal Fc receptor (FcRn)
 - immunoglobulin G clearance mechanisms, 242–243, 253–254
 - reproductive/developmental toxicity testing, 362–370
- Neonatal/juvenile monkeys, toxicity studies, pharmacological activity, 346
- Neo-organ development
 - cellular components, 808–812
 - clinical indications, 800–801
 - clinical testing protocols, 820–822
 - endpoint selection, 818–820
 - experimental design, 820
 - future research issues, 824
 - historical background, 801
 - model system selection, 815–818
 - neo-organ development, 804–806
 - preclinical testing, neo-organs, 821–822
 - preclinical testing and production process, 821–822
 - prototype definition and testing, 820–821
 - raw material testing, 808–815
 - regulatory issues, 788
 - safety studies, 806
 - scaffold materials, 814, 821
- Neopterin, as biomarker, safety pharmacology applications, 321–323
- NeoR gene, gene therapy products, 716–718
- Neural tissue, cross-reactivity assay pattern classifications, 228–230
- Neuropharmacology studies, design and cost estimates, 852, 887–889
- Neutralizing antibody assay, immunogenicity risk assessment, 482
- Niemann-Pick disease, acid sphingomyelinase therapy, 532–533
- Non-A, non-B hepatitis (NANB), evolution of, 670
- Nonhuman primates (NHP)
 - first-in-human (FIH) trials, preclinical transition to, 972, 975
 - immunotoxicity testing, 351–352
 - design and cost estimates, 855, 873
 - oligonucleotide safety pharmacology, cardiovascular safety, 552
 - oncology drugs, preclinical safety evaluation, 580–584
 - protein scaffold therapeutics assessment, 639–641
 - reproductive/developmental toxicity studies
 - basic principles, 371
 - embryofetal development, 387–390
 - fertility and early embryonic development, 382–384
 - immune system pre- and postnatal development, 392–393
 - monoclonal antibodies, 362–370
 - prenatal/postnatal development, 385–386
 - reproductive failure, 390–392
 - species selection criteria, 381–382
 - toxicity studies, pharmacological activity, 344–347
- Nonnatural amino acids, genotoxicity testing, 507
- Non-protein-peptide-based biologics, Japanese points-to-consider documents on, 103
- Nonrelevant toxicities, oligonucleotide therapeutics, 547–548
- Nonrodent studies
 - design and cost estimates
 - acute toxicity studies, 853, 859–860
 - cardiovascular studies, 854, 886–887
 - chronic toxicity studies, 853, 866–868
 - dose escalation study design and cost estimates, 853, 856–857
 - subchronic toxicity studies, 853, 862–863, 865–866
 - toxicity studies
 - molecular pharmacological activity, 344–348
 - peptides, preclinical assessment, 506
- Nonviral vectors, gene therapy products, 720–722
- No observable adverse effect level (NOAEL)
 - animal toxicity studies, predictive failure analysis, 329–331
 - combination biologic/device products, 793–794
 - drugs and biologics preclinical development programs, 134–135
- Fabrazyme® therapy, 528–529
- first-in-human (FIH) trials guidelines, 972
 - human equivalent dose calculations, 978–979
 - preclinical transition to, 975
 - starting dose calculations, 977
- gene therapy safety evaluation, 739–740
- high-risk compound evaluations, 84
- nonrodent toxicity studies, pharmacological activity, 347–348
- preclinical safety evaluation
 - animal models, 53–55

- No observable adverse effect level (NOAEL)
(*cont'd*)
determination of, 918–924
dose selection, schedule, duration, and response,
59
protein scaffold therapeutics assessment,
643–644
- OCT embedding media, tissue preparation, cross-
reactivity studies, 218
- Office of Combination Products (OCP)
combination biologic/device products
definitions, 784–785
regulatory guidelines, 800, 804, 807
neo-organ development, 803, 805, 807, 809, 811,
815, 817, 819
- Off-target effects
hybridization-dependent toxicities, 545–546
protein scaffold therapeutics assessment, 640–641
- OKT3
historical background, 107
murine monoclonal antibodies, 590–592
toxicity testing, 964
- Oligonucleotides
chemistry of
aptamers, 539
double-stranded RNAs-siRNA, 540–541
immunostimulatory compounds, 566
single-stranded structures, antisense activity, 540
future research issues, 552, 556
mechanisms and classification of, 539
pharmacokinetics, 541–544, 547
aptamers, 542
double-stranded RNA-based therapeutics,
544–545
phosphorothioates, 573
single-stranded morpholino oligomers, 544
reproductive/developmental toxicity testing,
369–372, 374–376
toxicity studies, 545–568
acute toxicity, 554–556
carcinogenicity, 568
genotoxicity, 548–549, 551
hybridization-dependent toxicity, 545
hybridization-independent toxicity, 545
immunotoxicity, 566–567
reproductive/endocrine toxicity, 565
safety pharmacology, 551–554
subchronic/chronic toxicity, 528–532
surrogate drugs, 545
- Omalizumab
carcinogenicity studies, 460, 462–464
preclinical safety evaluation, 597
reproductive/developmental toxicity testing,
360–372
toxicity testing, 964
- Oncaspar®, toxicity testing, 964
- Oncology drugs
preclinical safety evaluation
background, 613
clinical applications, 759
drug attributes, 578, 580
material production, 581
therapeutic targets and molecular classes,
576–577
toxicology models, 582–583
toxicity testing, 965
- Oncolytic virus, gene therapy, 715
replication-competent vectors, 726
- Ontak®
evaluation of, 662
toxicity testing, 965
- Oprelvekin
carcinogenicity studies, 457
toxicity testing, 964
- Organization for Economic Cooperation and
Development, good laboratory practice
requirements and practices
common U.S.-international elements in, 742
FDA requirement comparisons, 838
global compliance requirements, 835–836
history and scope, 832
- Organ regeneration, neo-organ product
development and, 805
- Organ weights
comparative organ/body fluid volumes, 920–921
preclinical safety evaluations and, 902
toxicity assessments, 771
- Ornithine transcarbamylase (OTC) deficiency,
gene therapy products, 717–718
- Osteocel®, toxicity testing, 952
- Ovarian tissue, immunoglobulin G clearance, 266
- p450 profiles, oncology drugs, preclinical safety
evaluation, 580
- Palifermin
carcinogenicity studies, 457, 459–460, 462–464
toxicity testing, 964
- Palivizumab
preclinical safety evaluation, 597
toxicity testing, 964
- Pancreatic enzymes, development of, 517
- Papain digestion, Fab fragment evolution, 213–214
- Parathyroid/parathyroid hormone analogues,
carcinogenicity studies, 457, 459–460,
462–464, 509, 511
- Patient characteristics, immunogenicity risk, 481
- Pegaptanib
carcinogenicity studies, 448
reproductive/developmental toxicity testing, 373,
375
- Pegasys®, toxicity testing, 953
- Peg-filgrastim
carcinogenicity studies, 457, 459–460
toxicity testing, 964
- PEGylated proteins
enzyme replacement therapies, 518
first-in-human (FIH) trials, dose estimations,
978
immunogenicity risk, 394

- Japanese points-to-consider documents, 88
- toxicity testing, 964
- Pepsin, Fab fragment evolution, 213
- Peptides and peptide hormones
 - basic properties, 509–511
 - carcinogenicity studies, 408–409
 - growth hormones, 457
 - insulin analogues, 458
 - insulin-like growth factor, 458
 - PTH/PTH analogues, 459
 - drug development overview, 503–505
 - Japanese points-to-consider documents, 103
 - preclinical toxicity assessment
 - carcinogenicity testing, 509, 511–512
 - chronic toxicity testing, 508
 - future research issues, 512–513
 - genetic toxicology, 506–507
 - recombinant vs. synthetics peptides, 512
 - safety pharmacology, 507–508
 - species selection, 502, 506
 - recombinant protein content, 32
 - toxins, immunotoxin development, 650
- Peripheral blood lymphocytes, safety
 - pharmacology studies, 328
- Peripheral nerves, immunoglobulin G transport/uptake, 247
- Phage display libraries, antibody evolution, 212–214
- Phagocytosis, antibody inhibition, 214–215
- Pharmaceutical legislation and regulation, EU
 - initiatives in, 71–72
- Pharmacodynamics (PD)
 - combination biologic/device products, 803–804
 - Japanese points-to-consider documents, toxicology studies, 103–104
 - relevant species criteria
 - binding properties, 282–283
 - overview, 277–279
 - species specificity, 279–282
 - safety pharmacology studies, flow cytometry and mononuclear cells, 328
 - U.S. points-to-consider documents, 107
 - in vivo effects, relevant species criteria, 184–188
- Pharmacokinetics (PK)
 - animal disease models, 301, 304
 - combination biologic/device products, 803–804
 - first-in-human (FIH) trials, interspecies scaling
 - human equivalent dose, 977–979
 - Japanese points-to-consider documents, toxicology studies, 115–116, 118
 - oligonucleotide drugs, 541–542
 - aptamers, 542
 - double-stranded RNA-based therapeutics, 544–545
 - phosphorothioates, 542–544
 - single-stranded morpholinos, 540
 - preclinical safety assessment design, 927
 - protein scaffold therapeutics assessment, 644–645
 - animal selection criteria, 637, 643
 - relevant species criteria, 281–286
 - disposition, 284–287
 - immunogenicity, 286–287
 - safety pharmacology testing
 - biopharmaceuticals, 315–316
 - integrated preclinical-clinical immunotoxicity assessments, 324–325
 - U.S. points-to-consider documents, 107
- Pharmacologically active dose (PAD)
 - first-in-human (FIH) trials guidelines, 965
 - human equivalent dose calculations, 977–979
 - starting dose calculations, 977–978
 - preclinical safety evaluation, 60–62
- Phase 1, preclinical development programs
 - drugs and biologics, support for, 140, 144
 - first-in-human (FIH) trials, 975
 - oncology drugs, preclinical safety evaluation, 578–580
- Phase 2, preclinical development programs, drugs and biologics, support for, 140–142
- Phase 3, preclinical development programs, drugs and biologics, support for, 142–144
- Phenotype/localization persistence, neo-organ development, cell sources, 811
- Phosphorothioate oligonucleotides (PS ODN)
 - acute toxicity studies, 554–555
 - carcinogenicity, 568
 - cardiovascular safety, 552
 - central nervous system safety, 582
 - genotoxicity studies, 540
 - immunotoxicity studies, 548
 - pharmacokinetics, 541–543
 - pulmonary/gastrointestinal safety, 553
 - renal safety, 552–553
 - subchronic/chronic toxicity studies, 556
 - cardiovascular effects, 560
 - hematologic effects, 560
 - hepatic effects, 562
 - immunologic effects, 561
 - renal function, 563
 - reproductive/endocrine toxicity, 561–563, 565–569
- Phototoxicity studies, design and cost estimates, 854, 876–877
- Physicochemical properties
 - comparability testing, 154, 156
 - recombinant proteins, 32–33
- Physiological reference values, preclinical safety assessments, 919
- Placental tissue, immunoglobulin G clearance, 258
- Plasma
 - immunoglobulin G clearance mechanisms
 - overview, 265
 - tissue catabolism and, 252
 - monoclonal antibody tissue cross-reactivity assay, 222–223
 - phosphorothioate oligonucleotide acute toxicity and, 554–556

- Plasmid DNA
 gene therapy products vs., 716
 nonviral vectors, 720–721
 viral vaccine development, 697
- Plasminogen inhibitor (PAI-1), pharmacokinetics studies, 285
- Platelet-derived growth factor (PDGF),
 becaplermin carcinogenicity studies, 457,
 459–463
- Points-to-consider documents
 cell-based therapies guidelines, 753, 755, 757,
 759, 761
- Japan, 99–101, 103, 105, 107–109
 antibodies, 102
 biopharmaceuticals classification, 100
 carcinogenicity studies, 105–106
 future applications of, 173
 genotoxicity studies, 106–107
 highest dose selection, 103
 metabolism studies, 104
 non-protein-peptide-based biologics, 103
 peptide-based biologics, 102
 protein-based biologics, 100–102
 repeat-dose toxicity study, 104–105
 reproductive and developmental toxicity
 studies, 105
 single-dose toxicity study, 104
 toxicological effects and pharmacological
 action, 103
 in vitro electrophysiological studies, 104
- United States, 113, 115
 administration/dose selection, 116
 exposure data, 118
 General Principles section, 115
 genotoxicity studies, 119
 immunogenicity, 117–120
 immunotoxicity studies, 119
 Manufacture and Testing of Monoclonal
 Antibody Products for Human Use, 208
 repeat-dose toxicity studies, 118–119
 reproductive/developmental studies, 119
 safety pharmacology/single-dose studies, 118
 species selection, 115–116
- Poly(ADP-ribose)polymerase (PARP), safety
 pharmacology studies, 328
- Polyethylene glycol (PEG), aptamer chemistry,
 539
- Polyethylene modified adenosine deaminase
 (PEG-ADA), development of, 518
- Polymeric immunoglobulin A receptor (pIgA-R/
 SC), immunoglobulin G clearance
 mechanisms, 255, 257
- Polymer materials, neo-organ development,
 scaffold properties, 814–815
- Pompe disease, Myozyme® therapy for, 531
- Popliteal lymph node assay (PLNA),
 autoimmunity, biopharmaceuticals for,
 492–493
- Positive tissue control, tissue cross-reactivity assay,
 218
- Postapproval requirements, biopharmaceuticals
 in European Union, 15–16
 in United States, 8–9
- Postimplantation studies, neo-organ products,
 811–812
- Postnatal development studies
 design and cost estimates, 854, 884–886
 reproductive/developmental toxicity testing
 immune system in nonhuman primates, 392–393
 nonhuman primates, 383, 389
- Potency testing, viral vaccine development, 702
- Potential elution, combination biologic/device
 products, 791–792
- Pragmatics-based strategies, good laboratory
 practice requirements and, 838, 840–842
- Preclinical development programs
 autoimmunity, biopharmaceuticals for, 491–493
 basic principles of, 127
 biologics vs. drugs
 alternative plans for biologics, 148–150, 152–154,
 156
 clinical development plan, 132–134
 critical decision making, 146–148
 essential components for, 135–136
 general assumptions, 130–131
 integrated plans, 145
 Phase 1 supports, 137–140
 Phase 2 supports, 140–142
 Phase 3 supports, 142–144
 specific assumptions, 134–135
 therapeutic target, mechanism of action, and
 clinical indication, 131–132
 traditional development plans, 135–148
 comparability testing, 171–172
 first-in-human (FIH) trial guidelines, transition
 to clinical trials, 975
 gene therapy, later stage product development,
 742
 good laboratory practice requirements, site
 selection criteria, 839–844
 hypersensitivity reactions, biopharmaceuticals
 for, 493–494
 immunotoxins
 overview, 624
 progress assessment, 660
 target antigens, 654
 Japanese practices, 96, 99
 neo-organ products, 804–808
 objectives and methods, 127
 protein scaffold therapeutics, 634–636
 somatic stem cells, 776
 timing issues, 108
 tissue-engineered products
 cellular components, 808, 810–812
 clinical indications, 815
 clinical testing protocols, 821
 endpoint selection, 818–819
 experimental design, 820
 future research issues, 825
 historical background, 716–717

- model system selection, 815
- neo-organ development, 804–820
- preclinical testing, neo-organs, 822
- prototype definition and testing, 820–821
- raw material testing, 808, 810–812, 814
- regulatory issues, 801–802, 804
- scaffold materials, 904
- Preclinical safety evaluation
 - ADME test system, 57
 - analogous products, 56–57
 - animal models, 54–55
 - animal models, 52–54
 - abnormal kinetic behavior of compound, 303
 - hyperlipidemia, 298
 - immunogenicity, 303–304
 - indications for, 301–302
 - overview, 296
 - species selection criteria, 46
 - translational research, humanized models, 296–297, 299
 - undesirable progression evaluation, 304–305
 - antibody screening assays, 59
- Basic Local Alignment Search Tool (BLAST),
 - cross-reactivity studies, 56
- biological oncology drugs
 - background, 575
 - clinical applications, 578–579
 - drug attributes, 578, 580
 - material production, 581
 - therapeutic targets and molecular classes, 576–578
 - toxicology models, 582–583
- blood products
 - coagulation disorders, gene therapy for, 677
 - future research issues, 676
 - genetically deficient protein diseases, 673
 - hemoglobin-based oxygen carriers, 672
 - immunogenicity, 675–676
 - immunoglobulins, 615
 - overview, 624
 - recombinant coagulation factors, 676–677
 - replacement therapy, coagulation factors, 675
- carcinogenicity studies
 - basic principles, 403
 - carcinogenic potential assessment, 413–426
 - cell line selection, 412
 - cellular-based therapies, 410–411
 - clinical indications, 412
 - gene therapies, 411
 - human malignancy patterns, 404–405
 - immunomodulators, 406, 426–440
 - indications for, 405–406
 - peptide hormone and growth factors, 406, 457–459
 - proliferation indexes, repeat-dose chronic toxicity studies, 423
 - risk communication and management, 426
 - rodent bioassay, 421
 - limitations, 468
 - short-term assay, 421–422
 - transgenic animals, 424
 - tumor host-resistance models, 423
 - in vitro cell proliferation, 425
- cell-based therapies, 764
 - adult stem cells, 759
 - endothelial progenitor cells, 760
 - exposure assessment, 767–769
 - ex vivo activated mononuclear leukocytes, 757
 - future research issues, 744
 - genotoxicity, 771
 - hematopoietic stem cells, 759–761
 - historical background, 716–717
 - human embryonic stem cells, 761
 - living autologous cells, 758
 - local tolerance, 772–773
 - mesenchymal stem cells, 760
 - pharmacology, 765–766
 - pre-preIND filing in U.S., 773
 - regulatory guidelines, 754–756
 - reproductive/developmental toxicity, 771
 - safety issues, 762–763
 - safety pharmacology, 766
 - somatic cell products, 776, 778
 - stem cell based therapies, 764
 - toxicity studies, 768–771
 - transition to clinical trials, 774–775
 - tumorigenicity, 771–772
 - xenogeneic cells, 762
- combination biologic/device products
 - antibody-coated stent example, 789
 - basic properties, 783, 787
 - biologic orientation assessment, 790
 - functionality assessment, 786–787
 - pharmacological/toxicological assessment, 792–795
 - potential elution species, 791–792
 - regulatory issues, 788, 797
 - testing strategies, 767
- comparative product attributes, 50
- cross-reactivity studies, 55–56
- design templates and cost estimates
 - acute toxicology studies
 - nonrodents, 853, 859–862
 - rodents, 853, 858
 - analytical/bioanalytical costs, 904
 - animal use, numbers, and gender, 915–916
 - biodistribution studies, 854, 877–878
 - blood sampling and maximum blood volume, 926–927
- carcinogenicity studies
 - CD@-1 mice, 853, 870–872
 - Sprague-Dawley rats, 852, 869
 - transgenic mice, 851, 871
- cardiovascular function
 - dog Purkinje fiber action potentials, 892–893
 - hemodynamics and, 886
 - hERG gene expression, 897
- chronic toxicology studies
 - nonrodents, 853, 865–868
 - rodents, 853, 863–864, 866–867

- Preclinical safety evaluation (*cont'd*)
- clinical pathology parameters, 901
 - dose escalation studies
 - nonrodents, 856–859
 - rodents, 855
 - dose selection and administration, 918–925
 - Draize scores, 903
 - embryofetal development and toxicokinetics
 - rabbits, 882–883
 - rats, 881
 - GLP compliance costs, 907–911
 - ICH guidance documents, 905
 - immunogenicity studies, Sprague-Dawley rats, 873
 - immunotoxicity studies, 853, 873
 - lymphoma mutagenesis, 896
 - maximum tolerated dose determination, 924
 - micronucleated polychromatic erythrocytes, 895
 - neuropharmacology studies, 852, 887
 - no observed adverse effect level determinations, 918, 924
 - organ weights, 902
 - overview, 844–845
 - pharmacokinetics/toxicokinetics, 925–926
 - phototoxicity studies, 876
 - pre- and postnatal development, 884
 - pulmonary assessment, 889–890
 - quality control, 695–696
 - reproductive/developmental toxicity studies, 910
 - special stains, 904–905
 - species selection, 914–915
 - subchronic toxicology studies
 - nonrodents, 853, 862–863
 - rodents, 853, 860–861
 - tissue cross-reactivity, 854, 899–901
 - tissue preservation, 902–903
 - toxicity assessments, 927–930
 - vaccine studies, 854, 875
 - in vitro chromosomal aberration, 897–898
- gene therapy, 727–740
- future research issues, 742–743
 - good laboratory practice guidelines, 738–739
 - non-GLP practices, 739
 - overview, 714–715
 - toxicology study design, 734–737
- history of, 45–47
- ICH S6 approach, 47–49
- ADME test system, 57–60
 - analogous products, 56–57
 - animal models, 52–54
 - species selection criteria, 54–55
 - comparative product attributes, 50–51
 - cross-reactivity studies, 55–56
 - future applications, 60–62
 - history of, 46–47
 - implementation, 49–52
 - test systems, 57–60
- immunotoxins
- overview, 649–650
 - target antigens, 650–651
 - toxins, 651
- implementation, 49–52
- neo-organ products, 806
- animal models, selection and testing protocols, 815–818
 - raw materials testing, 808
- principles vs. practices, 49
- protein scaffold therapeutics
- animal selection criteria, 637–641
 - dosage selection, 643–644
 - future research issues, 647–648
 - metabolism and pharmacokinetics, 645–646
 - program development strategy, 636–637
 - strategic overview, 633–636
 - study duration and classification, 641–643
 - toxicity biomarkers and indicators, 646–647
- safety pharmacology techniques
- integrated preclinical-clinical immunotoxicity assessments, 324–327
 - QT liability testing, 317–318
- somatic stem cells, 759
- test systems, 57–60
- toxicity studies
- design templates and cost estimates, 927–930
 - peptides and peptide hormones
 - carcinogenicity testing, 509–512
 - chronic toxicity testing, 508–509
 - future research issues, 512–513
 - genetic toxicology, 506–507
 - recombinant vs. synthetic peptides, 512
 - safety pharmacology, 507–508
 - species selection, 502, 506
- viral vaccines
- adjuvants and immunomodulators, 691–695
 - background, 684–685
 - biodistribution/integration assays, 701–702
 - carcinogenicity/genotoxicity testing, 699
 - contamination testing, 696
 - DNA plasmids, 704–705
 - DNA vaccines, 686–689
 - HIV case studies, 702–706
 - immunogenicity/toxicity studies, 696–697
 - mixed modality paradigms, 691, 705–706
 - quality control testing, 695
 - recombinant protein vaccines, 685–687
 - regulatory guidelines, 695–702
 - repeat-dose study, 699–700
 - reproductive toxicology, 701
 - safety pharmacology, 700
 - single-dose study, 699
 - species selection, 697–698
 - study design, 701
 - synthetic peptides, 512
 - virulence and potency testing, 702
 - virus-based vectors, 689–691
 - virus-like particles, 686
- Predictive failure analysis, animal toxicity studies, 328–331
- Predictive Safety Testing Consortium (PSTC), carcinogenicity studies, 403–404

- Pregnancy category C designation
 protein scaffold therapeutics assessment, 643
 reproductive/developmental toxicity testing, 375
- Pre-IND submission guidelines, cell-base therapies, 773–774
- Prenatal development studies
 design and cost estimates, 855, 884–886
 reproductive/developmental toxicity testing
 immune system in nonhuman primates, 392–393
 nonhuman primates, 392
- Primary mode of action (PMOA), combination biologic/device products, 785–788
- Primate supply and use
 EU guidelines on, 80–83
 toxicity studies, 344–348
- Primatized® monoclonal antibody,
 immunomodulatory biopharmaceuticals,
 in vivo testing, 615–621
- Process analytical technologies (PAT) initiative,
 good manufacturing practices and, 162
- Proliferation indexes, carcinogenicity studies,
 repeat-dose chronic toxicity studies, 423
- Proof of concept (POC) studies
 combination biologic/device products, 785
 animal models, 794
 gene therapy products, 728–732
- Proposed Approach documents, cell-based therapies guidelines, 754–757
- Protein-based biologics, Japanese points-to-consider documents, 103–107
- Protein blocks, tissue cross-reactivity assay, 220
- Protein purification and characterization
 biopharmaceutical production and, 22
 immunogenicity risk, 481
 immunomodulatory biopharmaceuticals, 603
 pharmacokinetics/toxicokinetics studies, 925–926
 recombinant protein content, 32
 reproductive/developmental toxicity testing, 371–375
- Protein scaffold therapeutics, preclinical safety evaluation
 animal selection criteria, 637–641
 dosage selection, 643–644
 future research issues, 647–648
 metabolism and pharmacokinetics, 645–646
 program development strategy, 636–637
 strategic overview, 633–636
 study duration and classification, 641–643
 toxicity biomarkers and indicators, 646–647
- Protein therapeutics, first-in-human (FIH) trials guidelines
 estimation examples, 979–981
 human equivalent dose, 978–979
- Protocol development, good laboratory practice requirements, 845
- Prototype development, neo-organ products,
 804–806
 clinical testing transition, 820–821
- Public Health Service (PHS) Act, good laboratory practice requirements and practices, 832–833
- Pulmonary safety pharmacology
 design and cost estimates, 855, 889–890
 oligonucleotide therapeutics, 553
- Pulmozyme®, toxicity testing, 954
- Purity requirements, recombinant proteins, 32
- Pyrogen testing, preclinical safety assessments,
 quality evaluation, 913–914
- QT liability testing
 background and history, 316–317
 clinical evaluation, biopharmaceuticals, 318–320
 preclinical evaluation, 318
- Quality assurance units (QAUs)
 good laboratory practice requirements,
 preclinical development programs,
 844–845
 good laboratory practice requirements and practices, 834–835
- Quality systems regulation (QSR)
 good manufacturing practices and, 162
 neo-organ products, scaffold materials, 814–815
- Quantitative polymerase chain reaction (Q-PCR)
 assay, gene therapy safety evaluation,
 740–742
- Rabbits
 embryofetal development and toxicokinetics studies, design and cost estimates, 853, 881–883
 reproductive/developmental toxicity testing
 basic principles, 380
 monoclonal antibodies, 368–370
 vaccine testing in, design and cost estimates, 854, 875
- Raw material testing
 neo-organ product development, 808–812
 preclinical safety assessments, quality controls, 916–918
- Receptor presence and distribution, relevant species criteria, 191–193
- Recombinant adeno-associated viral vectors,
 722–723
- Recombinant DNA Advisory Committee (RAC),
 gene therapy product regulation, 719–720
- Recombinant DNA technology
 blood products, coagulation factors, 676–677
 preclinical safety evaluation, monoclonal antibodies, 597–598
- Recombinant hemophilia factors, hypersensitivity,
 490–491
- Recombinant human acid spingomyelinase (rhASM), development and regulation,
 533
- Recombinant human α -galactosidase (r-h α GAL)
 development, 528–529

- Recombinant human granulocyte colony stimulating factor (rhG-CSF), pharmacodynamics, relevant species criteria, 280
- Recombinant human keratinocyte growth factor (rHuKGF), carcinogenicity studies, 461
- Recombinant human proteins, reproductive/developmental toxicity testing, 370–375
- Recombinant interleukin-2 (rIL-2), autoimmunity, 488–489
- Recombinant peptides, preclinical assessment, 512
- Recombinant proteins
 - biologic activity, 31
 - carcinogenicity studies, insulin analogues, 457–459
 - enzyme replacement therapies, regulatory guidelines, 525–534
 - expression systems for, 23–24
 - immunochemical properties, 30–31
 - lysosomal storage disease therapies, 520–521
 - physicochemical properties, 31
 - product content, 32
 - production and acceptance criteria, 28–29
 - purity and potential impurities, 32
 - release criteria for, 32
 - transgenic production, 32
 - viral vaccine development, 685–686
- ReFactor®, preclinical safety evaluation, 675
- Regenerative medicine
 - defined, 750
 - neo-organ development
 - clinical indications, 800–801
 - future research issues, 824
- Registration phase, preclinical development programs, drugs and biologics, support, 142–144
- Regulatory guidelines
 - autoimmunity and hypersensitivity, 491
 - biopharmaceuticals
 - in European Union, 12–13, 71–81
 - in United States, 4–8
 - cell-based therapies, 753–757
 - combination biologic/device products, 788, 797
 - comparability testing
 - EMA guidelines, 166
 - FDA guidelines, 165–166
 - ICH guidelines, 166–168
 - drugs and biologics development, 130
 - enzyme replacement therapy, 526–527, 534
 - acid sphingomyelinase, 532–533
 - Aldurazyme®, 530–531
 - Cerezyme®, 526–528
 - Fabrazyme®, 528–529
 - Myozyme®, 531–532
 - first-in-human (FIH) trials, safe starting doses, 975
 - gene therapy products, 718–719
 - global regulation guidelines, 718–719
 - good laboratory practice requirements and practices
 - basic elements of, 833–835
 - cell-based therapies, toxicity studies, 767–771
 - compliance strategies, pragmatic approach to, 839–840
 - FDA vs. OECD regulations, 838–839
 - future research and regulatory issues, 846
 - gene therapy safety evaluation, 738–739
 - global regulations and compliance, 837–838
 - history and scope, 832–833
 - ICH S7A safety pharmacology guidelines, 312
 - immunotoxicity testing, 349–353
 - preclinical studies site selection, 840–845
 - regulatory background, 829–831
 - U.S. regulations and compliance, 835–836
 - monoclonal antibody guidelines, 208–209
 - neo-organ product development, 804–806, 812
 - safety pharmacology techniques, integrated preclinical-clinical immunotoxicity assessments, 324–325
 - U.S. biotechnology products regulation, 113
- Release criteria, recombinant proteins, 30–33
- Relevant species criteria (animal models)
 - basic principles, 181–185
 - biologics development plans, 148–153
 - ex vivo biological effects, 188–191
 - fixed endpoint assays, 189–190
 - signaling assays, 190–191
 - ex vivo/in vitro biopharmaceutical interaction, 193–197
 - flow cytometry binding assays, 194–196
 - in vitro binding, 196–197
 - Japanese selection guidelines, 95
 - neo-organ product testing, 815–818
 - pharmacodynamics
 - binding properties, 282–283
 - overview, 277–279
 - species specificity, 279–282
 - pharmacokinetics, 283–288
 - disposition, 284–286
 - immunogenicity, 286–288
 - preclinical safety evaluation, animal models, 55
 - receptor presence and distribution, predicted tissues, 191–193
- in silico analysis, 199–204
 - microarray data, 201–204
 - sequence homology, target proteins, 199–201
- toxicity studies
 - gene therapy products, 733–734
 - human/primate molecular pharmacological activity, 348–349
 - nonrodent molecular pharmacological activity, 345–348
 - rodents/nonrodents, 344–345
 - transcript profiling, 196–199
 - U.S. guidelines, 115–116
 - in vivo pharmacodynamics, 185–187

- Renal function
 - oligonucleotide therapeutics
 - safety pharmacology, 551–554
 - subchronic/chronic toxicity effects, 558–561
 - proximal tubular epithelium, immunoglobulin G clearance, 252
- ReoPro®
 - platelet inhibition, 214–215
 - reactions to, 234–237
 - valence properties, 234–235
- Repeat-dose toxicity studies
 - biopharmaceuticals, 964–965
 - Fabrazyme® development, 529
 - immunotoxin evaluation, 654–655
 - Japanese points-to-consider documents, 107–108
 - proliferation indexes, carcinogenic potential, 423
 - U. S. points-to-consider documents, 118–119
 - viral vaccine development, 699–700
- Replication competent lentivirus (RCL), gene therapy products, 725–726
- Replication-competent oncolytic vectors, gene therapy products, 727
- Replication competent retrovirus (RCR), gene therapy products, 724–725
- Replication competent vaccinia (RCV), gene therapy products, 727
- Replication-deficient vectors, gene therapy products, 722–726
 - adeno-associated viral vectors, 723–724
 - adenoviral vectors, 722–723
 - retroviral/lentiviral vectors, 724–726
- Reporter gene imaging, cell-based therapies exposure assessment, 768
- Reproductive/developmental toxicity studies
 - biopharmaceuticals, 965
 - future research and technology developments, 371–375
 - historical background, 357–359
 - limited species cross-reactivity, 361
 - monoclonal antibodies, 362–370
 - nontraditional compounds, 370–371
 - small- vs. large-molecular weight drugs, 359–361
 - cell-based therapies, 771
 - design and cost estimates, in Sprague-Dawley rats, 855, 879–880
 - immunotoxins, 661–662
 - Japanese points-to-consider documents, 108
 - nonhuman primates, biopharmaceutical assessment
 - basic principles, 379–381
 - embryofetal development, 386–390
 - fertility and early embryonic development, 382–385
 - immune system pre- and postnatal development, 392–393
 - prenatal/postnatal development, 385–387
 - reproductive failure, 390–392
 - species selection criteria, 381–382
 - oligonucleotide therapeutics, 565–566
 - oncology drugs, preclinical safety evaluation, 583–584
 - protein scaffold therapeutics assessment, 642–643
 - U. S. points-to-consider documents, 119
 - viral vaccine development, 701
- Reproductive failure, reproductive/developmental toxicity testing, nonhuman primates, 390–392
- Request for Designation (RFD) documentation, neo-organ development, 803–804
- Research and development, biopharmaceuticals in European Union, 13–14
 - in United States, 8
- Repleplase, toxicity testing, 956
- Retina, immunoglobulin G transport/uptake and, 246
- Retroviral vectors, gene therapy products, 724–726
- RGD heptapeptide, chronic toxicity studies, 508–509
- Rhesus monkeys, reproductive/developmental toxicity testing in, 381–382
- Risk assessment methodology
 - carcinogenicity studies, 400–404
 - management and communication, 463–470
 - with preclinical assessment, 444–455
 - preclinical carcinogenic potential assessment, 413–426
 - immunomodulatory biopharmaceuticals, 621–624
 - neo-organ materials, 812–813
- Rituximab, toxicity testing, 957
- RNA, immunostimulatory oligonucleotide chemistry, 539–540
- RNA-induced initiation of transcriptional gene silencing (RITS) complex, oligonucleotide therapeutics, hybridization-dependent toxicities, 546
- Rodent studies
 - carcinogenicity studies
 - basic principles, 400–404
 - cell line criteria, 410
 - cellular-based therapies, 410–411
 - design and cost estimates, 855, 869–872
 - immunomodulators, 403–410
 - peptide hormones and growth factors, 406
 - preclinical carcinogenic potential assessment, 421
 - design and cost estimates
 - acute toxicity studies, 853, 858–859
 - biodistribution studies, 854, 877–878
 - chronic toxicity studies, 853, 866–867
 - dose escalation study design and cost estimates, 853, 855–856
 - embryofetal development and toxicokinetics analysis, 854, 881–882
 - liver assays, 854, 893–894
 - lymphoma mutagenesis, 854, 896–897
 - micronucleated polychromatic erythrocytes, mouse bone marrow, 854, 895–896

- Rodent studies (*cont'd*)
- neuropharmacology studies, 854, 887–889
 - phototoxicity studies, 854, 876–877
 - prenatal/postnatal development studies, 854, 884–886
 - pulmonary assessment, 854, 889–890
 - reproductive/developmental toxicity studies, 854, 879–880
 - subchronic toxicity studies, 853, 860–861, 863–864
- immunotoxin evaluation, 654–659
- preclinical safety evaluation
- acute toxicity studies, 853, 858–859
 - chronic toxicity studies, 853, 866–867
 - dose escalation study design and cost estimates, 853, 855–856
 - phototoxicity studies, 854, 876–877
 - subchronic toxicity studies, 853, 860–861, 863–864
- protein scaffold therapeutics assessment, 639–641
- reproductive/developmental toxicity testing
- basic principles, 379
 - monoclonal antibodies, 368–370
- safety pharmacology, peptides, 507–508
- toxicity studies
- design and cost estimates, 853, 855–867
 - molecular pharmacological activity in, 344–345
 - peptides, preclinical assessment, 506
- Route of administration
- biologics, preclinical development programs, route changes, 153, 156
 - enzyme replacement therapies, 520, 522
 - gene therapy products, in vivo toxicity studies, 736–737
 - ICH S6 protocols, U.S. selection criteria, 114–117
 - immunogenicity risk, 394
 - immunotoxin evaluation, 654–655
 - phosphorothioate oligonucleotide pharmacokinetics, 540–544
 - preclinical safety evaluations, design specifications, 922
- Safety factors, first-in-human (FIH) trials, human equivalent dose calculations, 979
- Safety pharmacology
- acid spingomyelinase development and regulation, 532–533
 - biopharmaceuticals, 314–316
 - cell-based therapies, 762–763, 766–767
 - Fabryzyme® therapy, 528–529
 - future research issues, 331
 - immunotoxin evaluation, 656–661, 660
 - integrated preclinical-clinical immunotoxicity assessments, 325–328
 - immunosuppressive activity evaluation techniques, 327–328
 - regulatory guidelines, 325–327
 - oligonucleotide toxicity, 551–554
 - oncology drugs, preclinical safety evaluation, 582–584
 - peptides, 507–508
 - pharmacodynamic measures, flow cytometry and blood mononuclear cells, 327
- preclinical safety evaluation
- AME test system, 57–60
 - analogous products, 56–57
 - animal models, 56–57
 - animal disease models
 - abnormal kinetic behavior of compound, 303
 - hyperlipidemia, 298
 - immunogenicity, 303–304
 - indications for, 300–302
 - overview, 293–296
 - translational research, humanized models, 296–299
 - undesirable progression evaluation, 302–303
 - animal models, 52–54
 - species selection criteria, 54–55
 - antibody screening assays, 55–59
 - Basic Local Alignment Search Tool (BLAST), cross-reactivity studies, 56
 - comparative product attributes, 50–51
 - cross-reactivity studies, 55–56
 - history of, 46–47
 - ICH S6 protocol, 47–49
 - ADME, 57–60
 - analogous products, 56–57
 - animal models, 52–54, 52–57
 - comparative product attributes, 50–51
 - cross-reactivity studies, 55–56
 - future applications, 60–62
 - history, 46–47
 - ICH S6, 47–49
 - implementation, 49–50
 - principles vs. practices, 49
 - test systems, 57–60
 - predictive safety biomarkers, standard toxicology protocols, 321–323
 - cell proliferation/apoptosis in tissue samples, 324
 - CNS assessments, 321
 - end-organ toxicities, 324
 - inflammation/immune activation/suppression, 321–323
 - QT liability/torsadogenic potential, new drug development
 - background and history, 316–317
 - clinical evaluation, biopharmaceuticals, 318–320
 - preclinical evaluation, 318
 - regulatory definition, 312
 - small molecules, “core battery” approach, 312–313
 - viral vaccine development, 700
- Salivary glands, immunoglobulin G clearance mechanisms, 252
- Sample analysis, preclinical safety evaluations, cost estimates, 851

- Scaffold materials
 - neo-organ development
 - regulatory guidelines, 804, 807
 - testing of, 814
 - tissue-engineered product development, 804–806
- Scientific advice, EU guidelines for, 78–79
- Scoring (test articles), monoclonal antibody tissue cross-reactivity assay, 193
- Screening assays, immunogenicity risk assessment, 475
- Self-inactivating (SIN) vectors, gene therapy products, 724–725
- Seminal fluid, immunoglobulin G clearance mechanisms, 258
- Sequency homology, in silico analysis, relevant species criteria, 199–200
- Serum creatinine
 - oligonucleotide toxicity and, 564–565
 - as predictive biomarker, safety pharmacology studies, 321–323
- Serum stability, immunotoxin evaluation, 654–655
- Short-term carcinogenicity assays, preclinical carcinogenic potential assessment, 421–423
- SIGLEC family receptors, predictive failure, animal toxicology studies, 330
- Signaling assays, ex vivo biologic effect, relevant species criteria, 184
- Simulect®, toxicity testing, 957
- Single-dose toxicity study
 - biopharmaceuticals, 963
 - Fabrazyme® development, 528–529
 - immunotoxin evaluation, 654
 - Japanese points-to-consider documents, 107
 - U. S. points-to-consider documents, 111
 - viral vaccine development, 699
- Single-stranded oligonucleotides
 - antisense activity, 540
 - basic properties, 537
 - morpholinos
 - basic properties, 540
 - pharmacokinetics, 542–544
- Site-directed immune complex disease, monoclonal antibodies, 236–237
- Skin tissue
 - Draize scores, 903
 - immunoglobulin G clearance mechanisms, 259
 - tissue-engineered product development and, 804–806
- Small interfering RNA (siRNA)
 - animal disease models, 294–296
 - translational research, 296–299
 - double-stranded oligonucleotides, 540
 - oligonucleotide therapeutics
 - acute toxicity studies, 556
 - hybridization-dependent toxicities, 546
 - lymphohistiocytic infiltrates, 560
- Small molecular weight compounds
 - genotoxicity testing, 337–340
 - oncology drugs, preclinical safety evaluation, 579–580
 - reproductive/developmental toxicity testing, 359–361
 - safety pharmacology, “core battery” approach, 312–313
- Somatic stem cells
 - cell-based therapies, 759
 - pharmacology/toxicology, 776–777
- Somatotropin
 - carcinogenicity studies, 431–436
 - toxicity testing, 962
- Species selection criteria (animal models). *See* Relevant species criteria
 - animal models, gene therapy products evaluation, 729–731
 - combination biologic/device products testing, 794–795
 - neo-organ product testing, 815–818
 - peptide toxicity studies, 502, 506
 - preclinical safety assessments, design criteria, 914–915
 - protein scaffold therapeutics assessment, 637–641
 - reproductive/developmental toxicity testing, 361, 381–382
 - safety pharmacology testing,
 - biopharmaceuticals, 315–316
 - viral vaccine development, 696–697
- Species specificity
 - oligonucleotides, 547–548
 - pharmacodynamics, relevant species criteria, 279–280
- Specificity technologies
 - immunotoxin evaluation, 654–655
 - preclinical safety evaluation, 49
- Spontaneous pathology, animal disease models, 294–296
- Sprague-Dawley rats, study design and cost estimates with
 - biodistribution studies, 854, 877–878
 - carcinogenicity studies, 853, 869–870
 - immunogenicity studies, 854, 873
 - neuropharmacology studies, 854, 887–889
 - reproductive/developmental toxicity studies, 854, 879–880
- Stability data, good laboratory practice requirements, preclinical development programs, 841–842, 844
- Staining techniques
 - design and cost estimates, 904–905
 - tissue cross-reactivity assay
 - adequacy of, 225–226
 - controls, 218
 - methodology, 219–220
 - pattern classifications, 227–230
- Standard of care (SOC), oncology drugs, preclinical safety evaluation, 579–580
- Standard operating procedures (SOPs), good laboratory practice requirements, preclinical development programs, 845

- Starting dose calculations, biologics, first-in-human (FIH) trials guidelines, 974–978
- “Stealth” liposome formation, oligonucleotide therapeutics, acute toxicity studies, 556
- Stem cells
 - neo-organ development, raw material testing, 810–812
 - preclinical safety evaluation, 764–765
- Sterilization methods, combination biologic/device products, 788
- Strategic planning, biologic/drug preclinical development programs, 156–157
- Streptavidin, biotin binding affinity, monoclonal antibody tissue cross-reactivity assay, 219–221
- Structure activity relationships (SAR), carcinogenicity studies, 402–404
- Study-specific procedures (SSPs), good laboratory practice requirements, preclinical development programs, 845
- Subchronic toxicity studies
 - design and cost estimates
 - nonrodents, 853, 862–863, 865–866
 - rodents, 853, 860–861, 863–864
 - oligonucleotide therapeutics, 556–565
- Supplementary evaluation test protocols, neo-organ products, 817
- Surface activation markers, safety pharmacology applications, 321–322
- Surrogate molecules
 - oligonucleotide therapeutics, 547–548
 - preclinical safety evaluation, analogous products, 56–57
 - toxicity testing, humans and chimpanzees, 348
- Synagis®, respiratory syncytial virus inhibition, 214–215
- Synthetic materials, neo-organ products, scaffold materials, 814–815
- Synthetic peptides
 - preclinical assessment, 512
 - viral vaccine development, 703
- Target antigens, immunotoxin development, 650–651
- Target product profile (TPP), drugs and biologics preclinical development programs, 132
- T cell dependent antibody response
 - immunomodulatory biopharmaceuticals, in vivo testing, 615–621
 - immunotoxicity testing, 350–353
 - integrated preclinical-clinical immunotoxicity assessments, 326–328
 - oligonucleotides, 567
 - predictive failure, animal toxicology studies, 330–331
 - reproductive/developmental toxicity testing, nonhuman primates, pre/postnatal development, 392–393
- T cell subsets, in vivo pharmacodynamics, relevant species criteria, 186–187
- Tegenero 1412
 - animal toxicity studies, 326–331
 - first-in-human (FIH) trials, preclinical transition to, 975
 - immunotoxicity testing of, 353
 - integrated preclinical-clinical immunotoxicity assessments and history of, 327–328
- Teriparatide, carcinogenicity studies, 450–451
- Testing protocols
 - combination biologic/device products, 789–792
 - good laboratory practice requirements, preclinical site selection criteria, 839–845
 - neo-organ development, 806–808
 - endpoint selection, 818–819
 - experimental design criteria, 819–820
 - model system selection, 815–818
 - quality controls, 916–918
- Therapeutic index estimation, preclinical safety evaluation, animal models, 51–55
- Therapeutic target identification, drugs and biologics preclinical development programs, 128–129
- Therapeutic targeting, oncology drugs, 578–580
- Three-segment evaluation techniques, reproductive/developmental toxicity testing, 373, 375, 381
- Thyrogen®, toxicity testing, 958
- Thyroglobulin, toxicity testing, 958
- Thyroid
 - autoimmunity, 488–489
 - immunoglobulin G clearance mechanisms, 261
- Time constraints, good laboratory practice requirements, preclinical development programs, 811, 815, 820
- Tissue catabolism, immunoglobulin G clearance mechanisms, 252
- Tissue cross-reactivity assay. *See also* Cross-reactivity studies
 - design and cost estimates, 854, 899–900
 - human tissue used in, 899–900
 - monoclonal antibodies
 - animal tissue, 216, 232–233
 - antibody-dependent cell-mediated cytotoxicity, 248, 251
 - assay control, 218
 - background staining, 226
 - CDR-mediated specific staining, 224
 - clinical plasma levels, 220, 222, 242
 - clinical significance, 121, 178
 - concentration selection, 223
 - context for, 230–231
 - epitope stability, 223
 - human tissue, 216, 233–237
 - human vs. animal tissue, 216–217
 - immune complex disease, 236–237
 - isotope control antibody, 218
 - microarray properties, 217
 - non-CDR-mediated specific staining, 221, 224
 - positive and negative controls, 218–219
 - preparation methods, 217–218

- scoring, 206, 226
- staining control, 218
- staining methods, 219–220
- staining pattern characteristics, 227, 232, 235
- test article affinity, 222
- test article forms, 220–222
- tissue and staining adequacy, 225–226
- valence, 234, 236
- protein scaffold therapeutics assessment, 640–641
- toxicity testing of biopharmaceuticals, 963
- Tissue-engineered products, preclinical development programs
 - cellular components, 808–812
 - clinical indications, 800–801
 - clinical testing protocols, 820–824
 - endpoint selection, 818–819
 - experimental design, 819–820
 - future research issues, 824
 - historical background, 716–717
 - model system selection, 815–818
 - neo-organ development, 804–820
 - preclinical testing, neo-organs, 821, 824
 - prototype definition and testing, 820–821
 - raw material testing, 808–815
 - regulatory issues, 801–804
 - scaffold materials, 812–815
- Tissue plasminogen activator (tPA)
 - pharmacodynamics, relevant species criteria, 278–279
 - pharmacokinetics assays, relevant species criteria, 286
- Tissue preservation, preclinical safety evaluations, 902–903
- Tissue properties
 - cell-based therapies exposure assessment, 767–768
 - cross-reactivity testing, human tissue properties, 900–901
 - monoclonal antibodies, cross-reactivity studies, 224, 226
- Tissue receptors, relevant species criteria, presence and distribution, 184, 193
- Tnkase™, toxicity testing, 959
- Top dose calculations, first-in-human (FIH) trials, 982
- Torsadogenic potential testing
 - background and history, 311, 316
 - clinical evaluation, biopharmaceuticals, 311, 317, 318
 - preclinical evaluation, 311, 318
- Toxicity studies. *See also* Acute toxicity studies; Chronic toxicity studies; Genotoxicity studies; Immunotoxicity studies; Subchronic toxicity studies
 - animal models, 300
 - number and gender criteria, study design, 910–911
 - biopharmaceuticals
 - carcinogenicity testing, 965
 - future research issues, 353–354, 966
 - genotoxicity, 909
 - immunotoxicity testing, 349–352, 354, 966
 - relevant species criteria
 - human/primate molecular pharmacological activity, 348–349
 - nonrodent molecular pharmacological activity, 345, 347–349
 - rodents/nonrodents, 344–345
 - repeat-dose toxicity testing, 964–965
 - reproductive/developmental toxicity, 965
 - single-dose toxicity testing, 963
 - specific compound survey, 932–963
 - tissue cross-reactivity testing, 963
 - cell-based therapies, 767, 771, 773–774
 - chronic toxicity studies, EU guidelines for, 88
 - combination biologic/device products, 792–798
 - enzyme replacement therapies, Cerezyme®, 527–528
 - Fabrazyme® development, 528
 - gene therapy products, 732–734
 - animal models, 733, 735
 - ex vivo transduced cells, 734
 - study design, 734–737
 - in vivo administration, 734, 736
 - genotoxicity, biopharmaceutical testing, 337–340
 - good laboratory practice requirements for, OECD vs. FDA comparisons, 838–839
 - high-risk compounds, EU regulatory guidance concerning, 83–85
 - immunotoxin development, 649–650
 - Japanese points-to-consider documents
 - pharmacological action and, 103, 105
 - repeat-dose toxicity studies, 104, 111
 - reproductive/developmental toxicity studies, 105
 - single-dose toxicity studies, 104
 - monoclonal antibody tissue cross-reactivity assay, 232–233
 - Myozyme® therapy, 522, 531
 - neo-organ product testing, endpoint selection, 818–819
 - oligonucleotides, 545–568
 - acute toxicity, 554–556
 - carcinogenicity, 568
 - genotoxicity, 548–551
 - hybridization-dependent toxicity, 545–546
 - hybridization-independent toxicity, 546–547
 - immunotoxicity, 561, 566–567
 - reproductive/endocrine toxicity, 537, 565
 - safety pharmacology, 551–554
 - subchronic/chronic toxicity, 556–565
 - surrogate drugs, 547–548
 - oncology drugs, preclinical safety evaluation, 582, 584–585
 - peptides and peptide hormones
 - carcinogenicity testing, 509–512
 - chronic toxicity testing, 508–509
 - future research issues, 512–513
 - genetic toxicology, 506–507
 - recombinant vs. synthetic peptides, 512

- Toxicity studies (*cont'd*)
- safety pharmacology, 507–508
 - species selection, 502, 506
 - preclinical safety evaluation
 - AME test system, 57–60
 - analogous products, 56–57
 - animal models, 52–54
 - species selection criteria, 54–55
 - biopharmaceuticals survey, 931–963
 - comparative product attributes, 50–51
 - cross-reactivity studies, 55–56
 - design criteria for, 928–931
 - history of, 33, 45
 - ICH S6 approach, 47–49
 - future applications, 60–62
 - implementation, 49, 51
 - principles vs. practices, 49
 - predictive safety biomarkers,
 - biopharmaceuticals, 320–325
 - protein scaffold therapeutics assessment
 - biomarkers and indicators, 646–647
 - duration and types of studies, 641–643
 - reproductive/developmental toxicity studies,
 - biopharmaceuticals
 - future research and technology developments, 371–375
 - historical background, 357–359
 - limited species cross-reactivity, 361
 - monoclonal antibodies, 362–370
 - nontraditional compounds, 370–371
 - small- vs. large-molecular weight drugs, 359–361
 - somatic stem cells, 749, 759
 - U.S. points-to-consider documents, 118–120
 - viral vaccine development and, 696–697
 - Toxicokinetic analysis
 - design and cost estimates
 - blood collection cost per time interval, 904
 - preclinical safety assessment design, 925–926
 - in rabbits, 854, 882–884
 - in rats, 854, 881–882
 - immunotoxins, 658–659
 - Toxin-conjugated antibodies, reproductive/developmental toxicity testing, 371
 - Toxin structure and properties, immunotoxin development, 650
 - Transcript profiling, relevant species criteria, 184, 196–197
 - Transendothelial-associated immunoglobulin G
 - biodistribution, intravascular-interstitial fluid compartment egress, 244–245
 - Transgenic animals. *See also* Knock-in animal models; Knockout animal models
 - animal disease models, 297
 - animals, manufacturing criteria, 28–29
 - antibody evolution, 212–214
 - biologics, preclinical development programs, 150–153
 - carcinogenicity studies, 421
 - design and cost estimates, 853, 871–872
 - gene therapy toxicity studies, 737
 - Japanese points-to-consider documents on, 107–109
 - preclinical safety evaluation, 53–57
 - recombinant proteins, 32–33
 - reproductive/developmental toxicity testing,
 - monoclonal antibodies, 362–370
 - safety pharmacology applications, 314–316
 - toxicity testing, 348–349
 - Translational studies
 - humanized animal disease models, 296–299
 - neo-organ product testing, 822
 - Transplantation techniques
 - neo-organ development, clinical indications, 800–801
 - stem cells
 - preclinical safety evaluation, 764–765
 - somatic stem cells, 777
 - Trastuzumab
 - pharmacodynamics, relevant species criteria, 279
 - reproductive/developmental toxicity testing, 370
 - toxicity studies, 945
 - Treatment duration, immunogenicity risk, antibody response, 480–482
 - Troponin-T, as predictive biomarker, safety pharmacology studies, 324–325
 - Tumor host-resistance models
 - carcinogenicity studies, 423–424
 - immunomodulatory biopharmaceuticals, 608–610
 - Tumorigenicity
 - carcinogenicity studies, 404–405
 - cell-base therapies, 771–772
 - somatic stem cells, 777
 - Tumor-infiltrating lymphocytes (TIL)
 - cell-based therapies, 757–758
 - gene therapy products, 716–718
 - Tumor necrosis factor-alpha (TNF α)
 - animal disease models, 301–302
 - autoimmunity, 487
 - Tumor progressors, immunomodulators, 608–612
 - Tumor promotion, immunomodulators
 - atypical promoters, 607–609
 - risk assessment, 606–609
 - Umbilical cord tissue and blood (UCB), neo-organ development, cell sources, 810–812
 - United Kingdom
 - cell-based therapies guidelines, 756–757
 - high-risk compound evaluations in, 83–85
 - United States
 - biopharmaceuticals
 - approval requirements, 9
 - definitions, 4–5
 - marketing and postapproval requirements, 9–10
 - regulations, 5–7
 - research and development requirements, 8
 - cell-base therapies, pre-preIND filing criteria, 773–774

- good laboratory practice requirements, 835–836
- ICH S6 implementation
 administration/dose selection, 116–117
 animal species selection, 115–116
 carcinogenicity studies, 120
 exposure limits, 118
 General Principles, 115
 genotoxicity studies, 119–120
 historical perspective, 113–115
 immunogenicity, 117
 immunotoxicity, 119
 local tolerance, 120
 regulatory issues, 111–113
 repeat-dose studies, 118–119
 reproductive/developmental studies, 119
 safety pharmacology/single-dose studies, 118
- U.S. Orphan Drug Act, lysosomal storage disease therapies, 520–521
- Uterine tissue, immunoglobulin G clearance, 258
- Vaccines. *See* Viral vaccines
- Valence properties, monoclonal antibodies, 234–235
- Vascular endothelial growth factor (VEGF)
 animal disease models, 301–302
 oligonucleotide toxicity, 566
 reproductive/developmental toxicity testing
 monoclonal antibodies, 367–370
 pegaptanib inhibition, 372–375
- Vascular leak syndrome (VLS), immunotoxin development, 652
- VB4-845 immunotoxin
 mechanism of action, 653
 preclinical safety assessment, 652–653
 toxicity studies, 656–661
- Vectibix™, toxicity testing, 960
- Vector sequencing
 gene therapy products, 720–727
 adeno-associated viral vectors, 723–724
 adenoviral vectors, 722–723
 biodistribution evaluation, 740–742
 nonviral vectors, 720–722
 replication-competent oncolytic vectors, 727
 replication-deficient viral vectors, 722–726
 retroviral and lentiviral vectors, 724–726
 in vivo administration, 736–737
 viral vaccine evaluation, 689–691
- Vehicle selection criteria, preclinical safety assessments, quality evaluation, 918–919
- Viral contamination, viral vaccine development and, 696
- Viral status, nonhuman primates, toxicity studies, pharmacological activity, 346–347
- Viral transcription, cell-based therapies exposure assessment, 769
- Viral vaccines, preclinical safety evaluation
 adjuvants and immunomodulators, 691–695
 background, 684–685
 biodistribution/integration assays, 701–702
 carcinogenicity/genotoxicity testing, 699
 contamination testing, 696
 design and cost estimates, 855, 875
 DNA plasmids, 704–705
 DNA vaccines, 686–689
 HIV case studies, 702–706
 immunogenicity/toxicity studies, 696–697
 mixed modality paradigms, 691, 705–706
 quality control testing, 695–696
 recombinant protein vaccines, 685–686
 regulatory guidelines, 695–702
 repeat-dose study, 699–700
 reproductive toxicology, 701
 safety pharmacology, 700
 single-dose study, 699
 species selection, 697–698
 study design, 698–702
 synthetic peptides, 703
 virulence and potency testing, 702
 virus-based vectors, 689–691
 virus-like particles, 686
- Viral vectors, gene therapy products, 726–727
- Virulence testing, viral vaccine development, 702
- Virus-like particles (VLPs), viral vaccine development, 686
- Waiver of carcinogenicity testing, 463–464, 466, 468
- Weight calculations, first-in-human (FIH) trials, human equivalent dose calculations, 979
- Whole organ replacement, neo-organ product development, 823–824
- Wound care, tissue-engineered product development, 804–806
- Xenogeneic cells, cell-based therapies, 762
- Xigris™, toxicity testing, 960

